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1. Introduction
Regenerative processes occurring under physiological (maintenance) [1-3] and pathological
(reparative) [4-6] conditions are a fundamental part of life, and vary greatly among different
species, individuals, and tissues. Despite the central nervous system (CNS) has been consid‐
ered for years as a perennial tissue, it has recently become clear that both physiological and
reparative regeneration occur also within the CNS to sustain tissue homeostasis and repair.
Importantly, the proliferation and differentiation of endogenous neural stem cells (NSCs)
residing within the healthy CNS, or surviving injury, are considered crucial in sustaining these
events. However, these processes are not robust enough to promote a functional and stable
recovery of the nervous system architecture. Thus, the development of cell-based therapies
designed to promote functional (direct vs. indirect) neural cell replacement was anticipated [7].
Nevertheless, most of the experimental cell therapies with neural lineage-committed progen‐
itors have failed to foster substantial repair in disease models where the anatomical and
functional damage is widespread and an inflamed and/or degenerative microenvironment co-
exists. Conversely, the systemic injection of in vitro expanded neural stem/precursor cells
(NPCs) – both as neurospheres as well as plastic-adherent monolayers - has provided a
remarkable amelioration of the clinico-pathological features of rodents affected by experi‐
mental inflammatory CNS disorders that include experimental autoimmune encephalomye‐
litis (EAE), cerebral ischemic/haemorrhagic stroke, spinal cord injury (SCI) and traumatic brain
injury (TBI). This has been shown to be dependent on the capacity of transplanted NPCs to
engage multiple mechanisms of action within specific microenvironments in vivo [8]. Among
a wide range of potential therapeutic actions – and in addition to the expected cell replacement
– this phenomenon may also occur via several bystander effects. These effects are heterogeneous
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and likely exerted by undifferentiated NPCs releasing immune regulatory and neuroprotec‐
tive molecules within specific microenvironments in response to local stimuli elicited by
inflammatory cells (therapeutic plasticity). The molecular and cellular mechanism(s) that sustain
the multifaceted therapeutic plasticity of NPCs remain far from being fully characterized [9].
The transplantation of undifferentiated exogenous NPCs very efficiently protects the CNS
from experimental chronic degeneration induced by inflammation both in small rodents (mice
and rats) [10-14] as well as in non-human primates [15]. Specific homing of systemically
injected NPCs is shown, so far, in experimental models of multiple sclerosis (MS), ischemic/
haemorrhagic stroke, SCI and TBI, and epilepsy. In vitro and in vivo data provide extensive
evidence of the molecular mechanisms behind the ability of NPCs to cross the blood-brain
barrier (BBB) and specifically accumulate at the sites of inflammation/tissue damage [16-18].
After entering the CNS using constitutively functional cell adhesion molecules and inflam‐
matory chemokine receptors, systemically injected NPCs accumulate at the level of perivas‐
cular CNS areas, where they establish atypical ectopic perivascular niches [16, 19]. In these areas,
a much likely active cell-to-cell communication takes place between transplanted NPCs and
the different cells of the atypical niche. As consequence of this, transplanted NPCs survive while
displaying undifferentiated features, and promote neuroprotection by releasing immune
modulatory molecules and neurotrophic factors in situ. Further evidence exists about an
additional peripheral immune-modulatory effect exerted by NPCs [20, 21]. Systemically
injected NPCs, in fact, enter also peripheral organs (e.g. draining lymph nodes and spleen)
were they accumulate at the boundaries of blood vessels and interact closely with lymphocytes
and professional antigen presenting cells (APCs), impairing their maturation and functional
activation [15, 22, 23].
NPC-based therapies have been therefore considered a plausible alternative strategy for the
treatment of neurological inflammatory disorders. However, some urgent and still unclear
questions have to be solved prior to straightforwardly translate most of these exciting
experimental observations into clinical medicines, such as: (i) the ideal stem cell source,
whether it has to be derived from pluripotent or multipotent sources; (ii) the ideal route of cell
administration, whether it has to be focal or systemic; (iii) the optimal time point for cell
administration, depending on the disease characteristics; (iv) the ideal balance between
differentiation and persistence of stem cells into the targeted tissue and (v) the ideal mechanism
of tissue repair to foster, whether it has to be cell replacement or tissue protection/healing.
Further, while some encouraging efforts are being devoted towards the development of
guidelines and establishment of explorative phase I clinical trials, still one of the major
constraints to the easy translation into human medicines is represented by the immunogenicity
of allogeneic stem cells, and the modest expandability of somatic human NPCs in vitro. Within
this scenario, the emerging figure of induced pluripotent stem (iPS) cells [24], induced neuronal
(iN) cells [25] and/or induced neural stem cells (iNSCs) [26] holds a new exciting promise.
In this chapter we will describe the most recent evidence of the remarkable therapeutic
plasticity of transplanted NPCs, when injected systemically in inflammation-driven CNS
degeneration experimental models. We will first focus on the evidence that inspired the
modern stem cell experimental therapies and then elaborate on the mechanisms regulating the
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cross talk between somatic NPCs and the dysfunctional microenvironment, both at the outer
and inner endothelial sides, and their clinico-pathological impact. Finally, we will discuss the
rationale of the most recent explorative trials that are bringing neural stem cell therapies into
the clinic.
2. Adult neural stem cells
2.1. A change in the dogma
Stem cells (SCs) possess the unique ability to self-renew and differentiate into different cell
types in the body. Their contribution is essential during embryonic and early post-natal life,
where they regulate morphogenesis and development by properly balancing proliferation and
differentiation. Though their number is destined to decrease with time, their presence in adult
organisms is still required to ensure homeostasis and repair. While the regenerating properties
of some tissues (e.g., the skin) and organs (e.g., the liver) are undisputed, the brain with its
unique organization and complexity was considered for long time an exception. In fact, the
dogmatic concept ‘no new neurons after birth’ (1913) expressed by Santiago Ramon y Cajal,
sustaining the limitation of neurogenesis to prenatal life, has been resonating for decades
within the scientific community, finally becoming an established belief. NSCs were thought
to be present within the brain only during the developmental stage. It was only in the late 60’s,
thanks to the availability of new techniques and advanced tools of investigation, that the
picture of the brain as an immutable organ started to be reviewed. Altman and colleagues,
using (3H)-thymidine pulses and autoradiographs, first demonstrated the presence of prolif‐
erating neurons in different regions of the post-natal brain in rats [1, 2, 27]. However, the
turning point was marked later in 1983 when Goldman and Nottebohm at Rockfeller Univer‐
sity (USA) described newly generated neurons at the level of the hyperstriatum ventrale, pars
caudalis (HVc), of the ventricular zone in intact adult female canaries [3] Subsequently,
numerous pioneering experiments contributed in demonstrating that specific regions of the
mammalian CNS undergo a continuous, though moderate, level of neurogenesis throughout
adult life [28].
2.2. Adult neurogenesis in physiological conditions
Today it is widely accepted that in the adult mammalian brain, newly generated cells derive
from NSCs residing in two regions [29], the ventricular-subventricular zone (V-SVZ) of the
forebrain lateral ventricles [2, 27, 30] and the subgranular zone (SGZ) of the dentate gyrus (DG)
of the hippocampus [1, 31, 32] (Figure 1). Because of the peculiar cellular organization and
exclusive microenvironment, these neurogenic regions are commonly referred to as germinal-
like niches [33, 34]. Although different, these two areas share an extremely organized and
specialized microenvironment where NSCs can strategically interact with a rich vascular
plexus [35, 36], while communicating with their progeny and neighbouring NSCs as well as
with differentiated neural cells trough specialized structures (e.g. primary cilium, basal and
apical processes). Altogether, these cellular components provide a unique milieu of extracel‐
Systemic stem cell therapies and brain diseases
http://dx.doi.org/10.5772/55426
289
lular matrix proteins and growth factors other than electrical stimuli, which define the dynamic
characteristic of the adult brain stem cell niches. In here, a strictly regulated balance between
proliferation and differentiation of NSCs ensure the maintenance of a constant, though
quantitatively modest, pool of progenitor cells throughout lifetime [37].
Figure 1. Schematic representations of the adult V-SVZ and SGZ neurogenic compartments.A and C, coronal sec‐
tions of the adult mouse brain showing the localization of the V-SVZ and SGZ of the hippocampus. B and D, cytoarchi‐
tecture of the V-SVZ (B), and of the SGZ of the DG of the hippocampus (D) in the adult mammalian brain. B,
Composition of the B1 cell domain into the V-SVZ. NSCs or type B1 cells (blue) extend from the proximal domain (do‐
main I, dark grey) to the distal domain (domain III, light grey). At the level of the ventricles, B1 cells contact the CSF
with their primary cilium extruding in the centre of a rosette of multi-ciliated ependymal cells (yellow), forming the
typical pinwheel-like structures on the ventricular surface. Here, NSCs can sense different signals circulating into the
CSF. In the distal domain, type B1 cells contact the blood vessels (red) with their specialized end-foot terminations. In
the intermediate domain (or domain II) type B1 cells give rise to IPCs (or type C cells, green), which are transit-amplify‐
ing cells generating neuroblasts (or type A cells, red). In this domain they are also in contact with their progeny, neigh‐
bouring cells and neuronal terminations. D, Composition of the RA domain at the level of the DG of the SGZ. RAs (or
type 1 cells, blue) extend from the hilus of the hippocampus (domain I, dark gray) to the IML (distal domain or domain
III, light gray). At the level of domain I, RAs sense the hilus microenvironment with their primary cilium and contact
other RAs, IPCs and blood vessels (red). RAs extend, trough their main shaft, into the distal domain where their arbori‐
sations receive signals from glial cells and neuronal terminations. RAs give rise to IPCs that mature (trough blue IPC1 or
type 2a cells, and light green IPC2 or type 2b cells) and differentiate into immature granule cells (IGC, red). During
their maturation, IPCs move from the proximal domain to the intermediate domain (or domain II, composed by SGZ
and GCL), where RAs receive signals from the progeny, neighbouring NSCs, interneurons (purple) and microglia (grey).
Finally IGC differentiate into mature GC (green), which extend their axons into the hilus and arbores dendrites into the
distal domain. Only few new-born neurons survive and become a long-lasting GC (pink).
2.2.1. Defining the cellular composition of the V-SVZ
The V-SVZ is situated in proximity of the lateral ventricles and contains slow-cycling SCs
with astroglial properties that express glial-fibrillary acidic protein (GFAP), called type B1
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cells. These cells give rise to intermediate progenitor cells (IPCs) or type C cells, which lose
GFAP immunoreactivity and acquire the expression of  the distal-less  homeobox (Dlx)-2.
These cells finally give origin to a pool of neuroblasts (type A cells) expressing the polysia‐
lylated form of neural cell adhesion molecule (PSA-NCAM) and the early neuronal marker
doublecourtin (DCX) [38].  Within rodent’s brain these neuroblasts form chains of migra‐
tion along the rostral migratory stream (RMS) to reach the olfactory bulb (OB), where they
terminally differentiate into at least six different subtypes of OB interneurons, depending on
their origin along the axes of the V-SVZ [39-41]. The V-SVZ niche (Figure 1 A-B) can be
divided in three differently organized domains where self-renewing B1 cells receive different
signals: proximal (or apical, I), intermediate (II) and distal (or basal, III) [37]. Type B1 cells retain
the typical apical-basal bi-polarity of their embryonic predecessors (radial glia) [42] extend‐
ing their processes along the three different domains and spanning the cerebrospinal fluid
(CSF) and the blood stream. In the proximal domain (composed by VZ and part of the SVZ)
Type B1 cells are enclosed within a cluster of ependymal (type E) cells, which sense the CSF
by means of motile cilia and create an appropriate gradient of molecules within the VZ [43].
Type B1  cells  are  therefore  physically  separated from the  ventricles.  Nevertheless,  their
contact with the CSF is still made possible by a single apical primary cilium extruding in the
centre of a rosette of type E cells. Typically, these apical end-foot terminations cluster together
to finally arise in the middle of a layer of E cells forming a characteristic pinwheel structure
resembling the embryonic forebrain germinal zone [36, 42]. Recently, it has been shown that
the  expression of  the  adhesion and signalling molecule  vascular  cell  adhesion molecule
(VCAM)-1 is critical for the correct positioning of these protrusions and the preservation of
this complex structure [44]. The small apical surface of B1 cells gives them the chance to
sense the CSF which contains soluble factors, such as insulin-like growth factor (IGF)-2, bone
morphogenetic proteins (BMPs) and Noggin, Wnts, Sonic hedgehog (Shh) and retinoic acid,
able to modulate NSCs behaviour [45]. At the same time a long basal process from the opposite
pole (distal domain), bridges B1 cells to the surrounding vascular plexus that runs in the
parenchymal side of the V-SVZ. Here, with a specialized end-foot termination, type B1 cells
contact endothelial cells (ECs) of the blood vessels, thus being influenced from soluble factors
released from ECs and/or possibly by molecules produced far away from the niche and
released in the blood stream. The intermediate domain (composed by the SVZ) contains B1
cell progeny, such as IPCs and neuroblasts, which participate in the maintenance of the niche
equilibrium perhaps trough mechanisms of direct feedback on NSCs providing informa‐
tion about the number of new neurons already generated. This balance, seems to be regulated
on one side by canonical Notch signalling trough ligands released or expressed by both IPCs
and neighbouring B1 cells [46, 47] and on the other side by neurotransmitters [e.g. gamma-
aminobutyric acid (GABA)] secreted by neuroblasts [48]. Importantly, while many studies
have focussed on the role of the microenvironment on the functionality of NSCs [49], much
less is known about the role that NSCs themselves exert on the definition of the niche. Recently
it has been shown that NSCs in the germinal niches do secrete a multitude of factors, among
which some with immune modulatory potentials that may influence the behaviour of the
surrounding cells, including microglia [50]. In parallel to the rodent CNS, the lateral wall of
the lateral ventricles (and the hippocampus) of the human brain contains NSCs that generate
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new neurons throughout adult life [51-53]. A total of four layers have been observed forming
the  human lateral  ventricular  wall,  which  comprise  a  monolayer  of  ependymal  cells,  a
hypocellular gap, a ribbon of astrocytes, and a transitional zone into the brain parenchyma
[52, 54]. Unlike the rodent and non-human primate brain [55], SVZ astrocytes of the human
brain are separated from the ependyma by a hypocellular gap [52]. The presence of promi‐
nent neurogenesis in the V-SVZ as well as of a RMS of migrating neuroblasts in the human
brain has been, however, intensively debated (for a preview, see [56]). Initially it was reported
the existence of a ribbon of astrocytes in the adult human V-SVZ that function as multipo‐
tent NSCs in culture although, only few proliferating cells and no evidence of chains of
migratory (β-III tubulin positive) immature neurons were observed [52]. In contrast, a later
report evidenced a robust cell proliferation in adult human V-SVZ and the presence of a
RMS of neuroblasts along a lateral ventricular extension that connects the lateral ventricle to
the OB [51]. Finally, two recent studies have provided evidence of a small ventricular lumen
connecting the lateral ventricles to the OB that is observed only in the foetal [57], but not
adult, human brain [55, 58]. Interestingly, the absence of this ventricular extension has been
confirmed even in the postnatal infant human brain [58], whereas a new medial migratory
stream (MMS) targeting the prefrontal cortex has been observed. Altogether these findings
suggest a dynamic evolution in human SVZ neurogenesis throughout life; with the infant
human SVZ, RMS and MMS activity, undergoing a progressive extinction at ages older than
18 months post-natal [58].
2.2.2. Defining the cellular composition of the SGZ
The second putative progenitor cell compartment is located in the SGZ of the DG of the
hippocampus (Figure 1C-D), namely the region of the brain involved in learning and memory
[1, 31, 32]. In this area, NSCs residing at the interface of the hilus and dentate gyrus are called
type-1 progenitors or radial astrocytes (RAs) [59] and they mainly correspond to astroglial cells
[60]. They mature in dentate granule cells and migrate towards the granule cell layer (GCL) to
finally integrate into hippocampal circuitry [59]. RAs, unlike B1 cells of the V-SVZ, are found
deeper into the brain parenchyma, surrounded by neurons, neighbouring RAs and other glial
cells but without any chance to contact the CSF [37]. However, B1 cells and RAs share some
key features: they both express astroglial markers, have ultrastructural characteristics of
astrocytes [41] and possess long processes reaching different compartments of the niche far
away from where the cell bodies reside [37]. RAs function as the primary precursors for the
generation of new dentate granule neurons, either directly or via the generation of IPC1 (type
2a cells) and IPC2 (type 2b cells) [61]. Similarly to the V-SVZ, also the SGZ can be subdivided
in a proximal, intermediate and distal domain along which RAs, with their polarized structure
(apical-basal), span from the hilus interface (proximal domain) to the inner molecular layer
(IML, distal domain) [37]. The proximal domain contains the primary cilium (important for
Sonic hedgehog (Shh) signalling), which sense the hilus microenvironment, and lateral
processes contacting other RAs and IPCs and, importantly, blood vessels. Here ECs release
vascular endothelial growth factor (VEGF), IGF and brain-derived neurotrophic factor (BDNF)
responsible for the regulation of the balance between proliferation and differentiation. RAs
have their cell bodies in the SGZ and extend their main shaft along the GCL, which compose
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the intermediate domain. In this area astrocytes receive inputs from their progeny, including
immature and mature granule neurons, IPCs and different neuronal and glial (e.g. microglia)
cell types. Type 2a cells expressing Achaete-scute homolog (Ascl)-1 (also known as Mash-1) -
a transcription factor important for neuronal commitment - are likely to originate in the
proximal domain and then rapidly migrate into the intermediate one, where they divide once
before differentiating into type 2b cells that will express DCX [62]. Similarly to V-SVZ, feedback
mechanisms from the progeny, such as canonical and non-canonical Notch signalling are
responsible for the quiescence of RAs or their transition to IPCs [63, 64]. In the IML, RAs
terminate with an elaborate and branched structure contacting glial cells, neuronal processes
and synapses. Although the contacts taking place in this area are still not completely under‐
stood, it seems probable that the GABAergic and glutamatergic inputs coming from inter‐
neurons and mossy cells, are important for the regulation of NSCs [65]. These astrocyte-like
cells of CNS germinal areas work as real pacemakers of adult neurogenesis, as they receive
internal and external inputs from their main shaft as well as from the end-foot of their radial
processes that contact ECs in the V-SVZ [42], or embedded into the molecular layer in the SGZ
[41]. However, despite the relatively high rate of neurogenesis, only a minority of new born
cells eventually survive, mature and integrate within the existing circuitries at the level of the
GCL of the hippocampus [66]. In parallel, postnatal SGZ neurogenesis in the human brain has
been demonstrated to occur across the lifespan [55]. Although the role of new born neurons
generating in the SGZ is not yet fully understood, increasing evidence suggest a possible role
in learning and memory function [55].
3. CNS inflammation effects on endogenous adult NSC niches
3.1. Switching from an immune-privileged to an immune-specialized state
Protection and homeostasis are fundamental keystones for the proper maintenance of the CNS.
Hence, brain and spinal cord must be kept under an extreme security state to ensure their fully
functionality and, ultimately, the survival of an organism. However, in the past the CNS has
been often regarded as an immune privileged site, where immune cells were not supposed to
enter and interact with cells of the nervous system. This common belief was strongly supported
by observations showing lack of lymphatic vessels, absence of parenchymal APCs, low
expression of constitutive major histocompatibility complex (MHC) class I and II molecules
within the brain parenchyma, as well as poor rejection of transplanted allo- or xeno-graft. In
the last decades this historical concept has been extensively revised, and there is now con‐
vincing evidence that the CNS is instead an immune specialized site, where a complex regimen
of immune surveillance does occur under physiological as well as pathological conditions and
is essential to guarantee its optimal functionality [67]. It is now clear that cells of both the innate
(microglia and monocyte-derived macrophages) and the adaptive (mainly CD4+ cells) immune
system are present within the brain parenchyma and exert beneficial effects on adult brain
plasticity and neurogenesis, as well as on the spontaneous attempt of the CNS to self-repair
following an injury [68].
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3.2. Effects of inflammation on neurogenesis
Studies conducted over the last decade have extensively proved that the immune and nervous
systems interact by engaging an active bidirectional crosstalk. Indeed, the expression of
receptors able to recognize inflammatory mediators released by activated immune cells allows
endogenous progenitor cells to increase their proliferation rate and specifically home to the
site of inflammation after a trauma. As a consequence, both acute [69, 70] and chronic CNS
inflammation [6, 71] has been shown to perturb the anatomical architecture and functional
activity of adult germinal niches.
Work on EAE mice, the most widely accepted model of MS, has shown that chronic CNS
inflammation in myelin oligodendrocyte glycoprotein (MOG)35-55-immunized mice causes a
transient decrease in the proliferation rate of both C and B1 type cells and a contemporary
increased accumulation of neuroblasts within the V-SVZ [6]. This effect, observed during the
peak of the disease, was attributed to cell non-autonomous factors, such as pro-inflammato‐
ry (Th1) cytokines [e.g. interferon (IFN)- and its intracellular effector Stat-1]. However, these
data contrast with other studies showing how inflammatory demyelination in MOG+/- mice
immunized with purified mouse myelin increased proliferation and mobilization of neural
progenitor cells from the V-SVZ of adult mice. Surprisingly, while new born cells generat‐
ed at the level of V-SVZ commonly intended to differentiate into neurons, in response to
EAE,  these  cells  were  able  to  generate  astrocytes  and  oligodendrocytes  as  well,  thus
suggesting  that  inflammation  can  diverge  (at  least  partially)  their  intrinsic  nature  [4].
Increased proliferation, measured in terms of BrdU-positive cells, has been found also at the
level  of  the  hippocampus  both  during  the  acute  and  chronic  phases  of  the  disease  in
MOG35-55 immunized mice. Similarly to the observed accumulation of neuroblasts in the
V-SVZ, autoimmune inflammation leads to increased numbers of immature DCX-positive
cells in the DG of the hippocampus [72]. Even though some alterations in the Notch, Wnt/β-
catenin, Shh, and BDNF signalling pathways have been observed, their real contribution to
the  deregulation  of  hippocampal  neurogenesis  in  the  course  of  chronic  autoimmune
neuroinflammation  needs  to  be  further  confirmed [72].  In  addition,  magnetic  resonance
imaging (MRI) techniques revealed structural alterations in the hippocampus, evidencing
marked hippocampal atrophy [73], which may correlate with deficits in attention, informa‐
tion processing capacity and long-term memory observed in the majority of MS patients.
Enhanced proliferation during the acute phase of the disease has been observed in proteoli‐
pid  protein  (PLP)139-151-induced  relapsing  EAE  in  SJL  mice.  However,  during  both  the
relapsing and chronic phase of the disease, the number of SVZ progenitors cells decreased,
without changes in the ultrastructural features of the type B, C or A cells, but accompa‐
nied by an impaired maturation of oligodendrocyte progenitor cells (OPCs). This suggests
that the chronic activation of glial cells (namely microglia and astrocytes) might be deleteri‐
ous for the repair potential of endogenous brain stem/progenitor cells. Indeed, minocycline-
induced inactivation of microglia during the chronic phase in relapsing-remitting EAE mice
was associated with an improvement in the number of proliferating Sox2/Bromodeoxyuri‐
dine  (BrdU)+  neural  stem cells  [74].  Finally,  models  of  targeted  focal  EAE,  obtained  by
stereotactic injection of cytokines [e.g. tumor necrosis factor (TNF)-α and INF-γ] in rodents
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pre-immunized with a sub-clinical amount of myelin peptides, allowed to better analyse the
time course effect of auto-immune inflammation in the neurogenic areas. In this experimen‐
tal model a decreased proliferation in the proximity of the V-SVZ was observed at 3 days,
followed by an increase at 7 days after the injection of the cytokines, suggesting a regenera‐
tive attempt at the level of the V-SVZ area. Interestingly, the concomitant death of neuro‐
blasts, the decreased type C cell proliferation, and the reduction of type A migrating cells,
during the initial phase, might explain the impaired long-term olfactory memory observed
by means of behavioural analysis [75]. Altogether, these findings suggest the existence of a
compensatory mechanism of the injured brain in its attempt to counteract neuronal injury
and disturbed conductivity resulting from T cell attack to the myelin sheaths wrapping the
axons, which is among the most accepted causes of EAE and MS [76].
In agreement with what described in animal models, SVZ activation and expansion have been
found at the level of periventricular active and chronic active lesions in MS patients, thus
suggesting that the repetitive exposure to inflammatory insults does not completely exhaust
the proliferative potential of the SVZ [77]. V-SVZ from post-mortem brains shows an altered
balance between neurogenesis and gliogenesis, likely related to these inflammation effects
within the neurogenic niche of MS patients [78]. Interestingly, the majority of MS patients show
deficits in attention, information processing capacity and long-term memory, thus suggesting
that neuronal damage in MS can result not only in motor and sensory deficits but also cognitive
impairment. In support of these MRI techniques revealed structural alterations in the hippo‐
campus, evidencing marked hippocampal atrophy [73].
Acute events, occurring in non-autoimmune diseases such as stroke, have been similarly
proved of giving rise to increased proliferation of endogenous NSCs in the V-SVZ. These cells
migrate from the neurogenic niche towards the ischemic boundary regions of the striatum and
cerebral cortex, where they differentiate into mature striatal neurons [79-81]. During this
(injury-reactive) site-specific homing, newly generated neuroblasts form chain-like structures
in association with reactive astrocytes and blood vessels in the striatum, a reminiscence of the
embryonic migration of type A cells along the RMS [82, 83]. Initially, this potential self-repair
mechanism was supposed to happen only during the acute post-stroke phase. However,
subsequent studies showed that stroke-induced neurogenesis is an extensive and long-lasting
(up to 2 weeks) event, with continuous production of mature striatal neurons for several
months after the insult [84]. Unfortunately, the vast majority of migrating new born neurons
die within few weeks after the ischemia, and only few damaged cells (about 0.1%) are replaced
by newly generated neurons [85]. Similar evidence of stroke-induced neurogenesis has been
reported in post-mortem brains, where new born neurons are present in the ischemic penum‐
bra surrounding cerebral cortical infarcts, preferentially localized in the vicinity of blood
vessels [80]. The identification of those factors able to influence NSCs proliferation, homing
and survival after stroke may have a great therapeutic impact. Several cytokines and growth
factors that may be released by injured cells are thought to play a substantial role in promoting
the observed neurogenic response after stroke. Among these, ciliary neurotrophic factor
(CNTF) [86], transforming growth factor (TGF)-α [87], VEGF [88], fibroblast growth factor
(FGF)-2 [89] and erythropoietin (Epo) [90] have been proposed.
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Much less is known about the presence of adult neurogenesis after SCI. Most likely, this can
be ascribed to a more diffuse scepticism concerning the existence of stem cells within the spinal
cord. Indeed, even if the spinal cord is generally considered a non-neurogenic tissue, multi‐
potent precursors can be isolated and propagated in vitro [91, 92]. In addition, spinal neuro‐
genesis has been shown to occur to a limited extent in response to several types of trauma
[93-95]. In a very recent study, the modulation of neurogenesis in the more canonical niches
of the adult brain has been investigated following SCI in rats. Interestingly, BrdU+ positive
cells were found to be significantly decreased both at the level of the V-SVZ and the SGZ in
subacute [15 days post injury (dpi)] condition. However, while V-SVZ proliferation returns to
normal levels at 90 dpi, this does not happen at the hippocampal level. This could be equally
explained by either a higher plasticity in the V-SVZ or a higher sensibility of the SGZ [96].
Alterations in adult neurogenesis have been extensively observed in a multitude of models of
other neurodegenerative diseases. Rats suffering by pilocarpine-induced temporal lobe
epilepsy (TLE), exhibit increased neurogenesis in the V-SVZ [97] as well as in the SGZ [98]
after a period of latency and then it lasts for several weeks following prolonged seizures
activity. Further, status epilepticus (SE) seems to accelerate the maturation and integration of
adult new born DG cells [99]. However, chronic TLE induces a decrease of neurogenesis, as
children affected by frequent seizures show decreased numbers of newly generated neurons
and proliferating cells [100]. Impaired (cell type specific) proliferation of V-SVZ as well as SGZ
progenitors has been observed also in experimental models of Alzheimer’s disease (AD) [101].
While it is not clear whether this is reflected in an increased [102] or decreased neurogenesis
[103], mainly because of the high number of different models used [104, 105], a recent study
suggested that abnormalities at the level of both the neurogenic niches might precede the onset
of amyloid deposition and memory impairments [106]. Interestingly, in post-mortem brains
of patients with AD, it has been observed an increase of neurogenesis into the SGZ accompa‐
nied by depletion in the V-SVZ [107].
3.3. The double face of inflammation
According to what described, it is suggestive that the CNS is able to start a beneficial, though
limited, process of self-repair. However, most of the new born cells generated following injury
are destined to die within few weeks, maybe due to a failure in their integration or due to the
inflammatory milieu. Even if these cells have been shown to fully differentiate into mature
neurons [82], the very low rate of occurrence imposes logical concerns regarding the thera‐
peutic value of this regenerative response to brain injury [81, 108]. Because of the rearrange‐
ments occurring in the neurogenic niches after an inflammatory event, the immune system has
been accredited as one of the major responsible of this failure. This assumption is further
corroborated by the observation that the increasing complexity of the immune system over the
evolutionary process has been accompanied by a concomitant loss of regenerative capacity
[109]. Also, several findings link inflammation to the pathogenesis of neurodegenerative
disorders and anti-inflammatory drugs seem to be promising candidates for their treatment.
Recent studies suggest that inflammation may indeed have a neuroprotective effect [110].
Nevertheless, the real effect of inflammation in several of these pathologies still needs to be
completely clarified.
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The early (acute) post-traumatic phase of a neuroinflammatory process involves the action of
resident microglial cells. These cells of myeloid origin are usually present in a resting but
dynamic state, ready to shift their activity and undergo morphological and functional trans‐
formations in response to any kind of brain damage or injury [111, 112]. While on one side the
selective ablation of microglia has been shown to exacerbate the ischemic injury in a mouse
model of focal cerebral ischemia [113], on the other side mounting evidence indicates that
chronic microglial activation may also contribute to the development and progression of
neurodegenerative disorders, mainly through the release of pro-inflammatory cytokines such
as interleukin (IL)-1, IL-6, and TNF-α [114]. As an example, infiltrating blood-derived macro‐
phages have been shown to exert a beneficial role in an experimental model of SCI, where they
contribute to limit the action of activated resident microglia, whose prolonged presence would
finally lead to detrimental consequences [115]. Indeed, when the activity of microglia is not
properly contained, their action may lead to a prolonged (chronic) inflammation eventually
culminating in the formation of fibrotic tissue.
Endogenous T cells are key components of the protective immunity process. As such, phys‐
iological trafficking of lymphocytes through the CNS is required to support the essential
function of immune surveillance [116]. Cellular composition analysis of the CSF of healthy
patients has revealed that up to 80% of the total number of cells is represented by central
memory and effector memory T-cells. This atypical composition, which is very different from
the one of the blood, also suggests a major role for the CSF in the defence of the CNS [117].
Indeed, the CSF drains the interstitial fluid of the CNS and brings CNS antigens to the cervical
lymph nodes, thus supplying for the absence of a proper lymphatic drainage [118, 119].
Following the seminal observation that self-specific T-cells recognizing myelin basic protein
were able to protect injured CNS neurons from secondary degeneration in a rat model of optic
nerve crash injury [120], several studies further supported the idea that T cell-dependent
autoimmunity might promote recovery from CNS injuries [121, 122]. These studies finally
culminated with the idea that boosting T-cell response to CNS antigens by means of immuni‐
zation with CNS myelin-associated self-antigens could have enhanced this therapeutic
potential [123-125]. Also, myelin-reactive T-cells possess neuroprotective effects, which may
be essentially attributed to their ability to release neurotrophic factors such as BDNF, nerve
growth factor (NGF) and CNTF [126]. Importantly though, auto-reactive T-cells showing this
protective effect may turn out to be harmful if escaping the control exerted by the immune
system, finally resulting into the development of autoimmune diseases such as MS. Therefore,
a strict control is required to finely tune the balance between the good and the bad [76].
To further complicate the scene, several inflammatory mediators, such as TNF-α, TGF-β, IL-1,
IL-6, IL-10 and IL-12 may have contrasting effects (e.g neuroprotective vs. neurotoxic) de‐
pending on the overall context. As an example, the role of IL-6 is crucial for the induction of
EAE [127], and its overexpression exacerbates tissue injury in experimental models of SCI [128,
129]. Also, high levels of this inflammatory marker in the blood of patients undergoing
inflammatory response after stroke correlates with the disease severity and poor clinical
outcome [130]. Accordingly, the use of monoclonal antibody directed towards IL-6 proved to
be beneficial in the treatment of acute SCI and MOG35-55-induced EAE [131, 132]. However,
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IL-6 knockout mice showed significantly increased of chronic (but not acute) lesion volumes
and worse long-term functional outcome after stroke [133]. This may imply the need of a finely
tuned regulation, most likely depending on their precise timing and location other than on the
specific nature of the disease. Indeed, while some pathologies such as MS, SCI, stroke, TBI and
are characterized by an acute inflammatory event followed by secondary neurodegeneration,
others, such as epilepsy, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Hunting‐
ton’s disease (HD) are instead caused by primary neurodegeneration subsequently leading to
secondary reactive inflammation [19].
As described in this paragraph, the CNS is able to regulate the proliferation rate within the
adult neurogenic niches as an extreme attempt to respond to damages in both primary and
secondary inflammatory neurodegenerative diseases. Nevertheless, this process is not robust
enough to effectively re-establish the complex functionality of the CNS. Therefore, protocols
aiming at pharmacological manipulation of endogenous precursors from germinal niche(s),
in vivo, might be therapeutically inefficacious in inflammatory CNS disorders. Thank to the
development of protocols allowing in vitro growth and large scale-up of brain-derived NPCs
[134], innovative therapies, for both acute and chronic CNS inflammatory disorders, based on
stem cell transplants have been proposed [7]. Transplantation of adult exogenous NPCs
represents, in fact, an alternative, and possibly more efficacious, therapeutic approach that
might overcome the limited endogenous repair. Motivated by the ambitious expectation to
achieve CNS repair (and/or regeneration) via functional neural cell replacement, many
different preclinical studies have evidenced a potential benefit of NPC-based treatments in
experimental animal models of several neurological diseases [8].
4. Exogenous NPC-based therapies: The systemic administration
4.1. Systemic injection and functional recovery
Following the seminal observation that systemically delivered NPCs were able to target an
intracranial tumour in rodent (both mice and rats) model of experimental brain tumours [135],
numerous studies started to investigate the validity of this administration route in a variety of
CNS disorders. Over the last decade, data have been provided on the feasibility of systemic
NPC transplants via either intravenous (i.v.) cell injection into the blood stream, or interacer‐
ebroventricular (i.c.v.)/intrathecal (i.t.) into the CSF, in experimental CNS disease models
[10-13, 16, 136-138]. Adult somatic mouse NPCs, administered 22 days post immunization
(dpi) greatly reduced the functional impairment observed in chronic MOG35-55-immunized
EAE mice [11]. Also, rat NPC neurospheres, administered i.c.v. or i.t. in rats affected by acute
EAE, attenuate the clinical symptoms when administered at the same day of disease induction
(0 dpi) [136]. Intravenous injected mouse NPCs were proved to be efficacious in PLP139-151
immunized relapsing EAE mice [16]. Indeed, mice, treated with NPCs at the disease onset or
at the time of the first relapse, recovered faster and showed a decrease in the relapse rate
compared to controls. At the end of the follow-up (90 dpi) both treatments resulted in a lower
relapsing remitting EAE cumulative score [16]. Finally, MOG35-55-immunized chronic EAE
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mice receiving either mouse neurospheres (i.c.v) or single cell NPCs (i.v.), at 6 and 8 dpi
respectively also showed significant clinical amelioration [20, 139].
The therapeutic efficacy of systemically administered NPCs has been later observed in a
different pathological context, such as stroke. Mouse somatic NPCs, systemically transplanted
3 days after middle cerebral artery occlusion (MCAo), resulted in a better recovery, signifi‐
cantly improving the neurological severity score starting from 18 days post transplantation
(dpt) until the end of the follow-up (30 dpt) [140]. Similar neurological improvements were
observed in rats subjected to MCAo and common carotid artery occlusion (CCAo) after i.t.
transplantation (7 days after stroke) of rat NPCs [141]. Significant locomotor recovery was also
observed after acute systemic NPC transplant in mice suffering from contusion SCI [13].
Similarly to rodent cells, human NPCs have been proved to be therapeutically efficacious.
Foetal NPCs administered either i.v. or i.t. at the disease onset, reduced the severity of
MOG1-125-induced chronic EAE in common marmosets [15]. Further, human embryonic stem
cell (ESC)-derived NPCs have been shown to reduce disease severity of chronic EAE mice
[142]. Human immortalized NPCs have been widely enrolled in stroke models. The systemic
injection of the HB1.F3 NPC line resulted in neurological improvements of rats treated 1 day
after MCAo or intracerebral hemorrhage (ICH) stroke models [12, 137, 138]. The same line
resulted therapeutically effective also in quinolinic acid-induced experimental HD in rats,
where NPCs administered intravenously at 7 days after disease induction, significantly
ameliorated the behavioural outcome [14].
All these evidences showing behavioural recovery upon systemic injection of NPCs in different
CNS inflammatory models, led to the investigation of the molecular mechanisms standing
behind, since this capacity bears the hope of developing less invasive surgical techniques to
implant therapeutic adult human stem cells into patients affected by highly debilitating CNS
disorders, such as MS, stroke, SCI, epilepsy, PD, AD and HD.
4.2. Homing capacity: NPCs breach the CNS barriers
Brain and spinal cord are protected by a complex control system, composed by tight barriers
shielding the action of a unique troop of immune cells. Indeed, to access the brain and spinal
cord parenchyma, circulating cells have to breach through all the barriers that closely seal the
CNS from the surrounding environment. Namely, these are the blood-brain barrier (BBB) at
the level of parenchymal capillaries and post-capillary venules, the blood-cerebrospinal fluid
barrier (BCSFB) at the level of the choroid plexus in the brain ventricles, and the blood-
leptomeningeal barrier (BLMB) at the level of the leptomeningeal/subarachnoid space. The
main role of these barriers is to maintain the chemical composition of the CNS microenviron‐
ment, thus ensuring the proper functionality of neuronal circuits, synaptic transmission and
remodelling, angiogenesis, and neurogenesis in the adult brain, while their rupture is involved
in many neuroinflammatory disorders [143]. Because of the existence of such barriers, the
access of systemically injected NPCs to the CNS parenchyma seems quite unlikely.
Structurally, the main component of the BBB is represented by specialized ECs characterized
by the absence of fenestrae, low pinocytotic activity and by the presence of intercellular tight
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junctions (TJs) [144]. This clutched arrangement prevents the free passage of molecules, while
the transport of nutrients into the CNS and the discard of toxic molecules into the circulation
is ensured by active mechanisms, thus guarantying a proper neuronal activity [145]. Moreover,
the BBB is an essential constituent of the so-called neurovascular unit, a boundary zone defined
on one side by the endothelium basement membrane (located in the abluminal side of the
vasculature) and on the other by the parenchymal basement membrane, which establishes the
ultimate border between the perivascular space and the CNS parenchyma. In post-capillary
venules these two membranes lay in close proximity, leaving just a narrow perivascular space
in between, which becomes more significant at the level of arteries and veins. In this area,
occasional APCs (leptomeningeal mesothelial cells) reside and play a major role in the
immunosurveilance program of the CNS. Finally, the inner and outer sides of the parenchymal
basement membrane are juxtaposed to the glia limitans, whose crossing seems to be crucial for
the effective triggering of a neuroinflammation process [146, 147]. The functionality of the BBB
in clinical situations, such as those occurring in some neurodegenerative disorders like MS,
ischemic stroke, sub-arachnoid haemorrhage, TBI and AD is markedly reduced, leading to an
increased permeability and trafficking of immune cells into the CNS parenchyma [148-152].
Most of the knowledge about the mechanisms that allow circulating cells to breach the
barrier(s) [117, 153, 154] and move into the CNS parenchyma comes from observations
conducted with models of CNS inflammation. Initial studies showed how intravenously
injected radioactively labelled encephalitogenic T cells were able to cross the BBB of healthy
recipients [153]. It was also shown that, while activation is mandatory for T-cells to cross the
endothelial barrier and reach perivascular spaces, antigen specificity is dispensable to further
cross the glia limitans and invade the CNS parenchyma after having encountered the appro‐
priate APCs [155].
The extravasation of specific T cells requires a multistep process [156]. The first step, known
as capture  (in non-inflamed endothelia) or tethering  (in inflamed endothelia) and rolling  is
represented by an initial,  transient contact  promoted by the specific  interaction between
members of the selectin and integrin families expressed by the activated endothelium with
their respective ligands on circulating immune cells.  It  has been shown how the recruit‐
ment  of  inflammatory  cells  across  the  BBB  involves  α4-integrin  and  its  ligands  of  the
immunoglobulin (Ig) superfamily, namely vascular cell adhesion molecule (VCAM)-1 and
mucosal  addressin cell  adhesion molecule  (MAdCAM)-1 [147].  Upon this  initial  contact,
circulating cells decrease their initial speed and resist the shear stress created by the blood
flow, mainly through endothelial intercellular adhesion molecule (ICAM)-1 and VCAM-1,
but not ICAM-2 [157]. Elegant studies have consistently shown that the inhibition of the
dimeric  α4β1-integrin  and  its  cognate  receptor  VCAM-1  on  the  activated  endothelium
prevented the accumulation of leukocytes in the CNS and the development of EAE [158].
Interestingly, when the inflammatory process is started, α4β1-integrin is no more dispensa‐
ble for T-cell capture or rolling [159].
The following step requires the firm adhesion and crawling of T-cells along the vascular wall.
This is orchestrated by some chemokines and chemoattractants, such as stromal cell-derived
factor (SDF)-1α/CXCL12 [160], monocyte chemoattractant protein (MCP)-1/CCL2 [161],
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regulated and normal T cell expressed and secreted (RANTES)/CCL5 [162], EBI1 ligand
chemokine (ELC)/CCL19, secondary lymphoid-tissue chemokine (SLC)/CCL21 released by the
inflamed endothelia and CCR7 [163]. By binding to their G-coupled receptor (e.g.: C-X-C
chemokine receptor -CXCR- type 4 for SDF-1 and CCR2 for MCP-1), these chemokines transmit
an inside out signalling to T-cell surface integrins, which undergo dramatic conformational
modifications thus increasing their avidity (specificity for the ligand). Once engaged in such a
firm adhesion, T-cells need to make their way through the endothelium. To this purpose they
start probing the vasculature to find the optimal site to breach the wall. Following adhesion
to blood vessel walls, leukocytes undergo a series of actin rearrangements that eventually mark
their transition to a more flatten and polarized shape [164]. Finally, T-cells cross the border
either by paracellular or transcellular diapedesis or by creating pores through the cells -
transcellular diapedesis -. While the former require the disassembly of the intercellular junction
structure, the latter involves the formation of “cell-in-cell” interactions through the arrange‐
ment of docking structures or transmigratory cups enriched in ICAM-1 and VCAM-1, which
partially embrace migrating leukocytes [165].
A very similar sequential process has been shown being recapitulated when systemically
injected NPCs specifically home to the site of damage. In fact, NPCs posses the ability to reach
the cerebral parenchyma where they eventually induce recovery in animal models of neuro‐
degenerative diseases such as EAE [10, 11] stroke [12, 166], SCI [167, 168], epilepsy [138, 169],
HD [14], other than glioblastoma [135, 170]. The first studies showing the extravasation
capacity of NPCs [10-12] clearly demonstrated that this capacity was strictly related to the
activation of the ECs by an inflammation process occurring within the brain. NPCs adminis‐
tered either i.c.v. or i.v. to healthy animals were, in fact, never observed inside the CNS, while
mainly accumulating in peripheral organs, or remaining confined in the ventricles or subar‐
achnoid space. Only after activation of endothelial cells, exogenous NPCs were observed to
accumulate into the CNS. Systemically injected NPCs are, in fact, able to follow a gradient of
chemoattractants (e.g. pro-inflammatory cytokines and chemokines) released by the inflam‐
matory lesions into the blood stream and CSF. Following these signals, NPCs rapidly reach
the source of pro-inflammatory molecules within and interact with the activated endothelial/
ependymal cells around inflamed CNS tissues. At this level, NPCs and endothelial cells start
an organized sequence of events resembling those described for T cell extravasation that allow
the selective entrance and specific homing of transplanted cells in multifocal inflammatory CNS
areas [16]. Interestingly enough, only small percentages (between 1-5%) of the systemically
administered NPCs actually infiltrate and integrate within the CNS [11, 13, 140]. Mouse SVZ-
derived adult NPCs transplanted in a subacute model of brain inflammation were shown to
adhere to the CD49d counterligand VCAM-1 [16]. Further in vivo experiments showed that
migration of mouse NPCs towards the site of damage is dependent on the CXCR4-SDF-1α
signalling in mouse models of MS and brain tumour [17, 171]. In stroke models, the up-
regulation of VCAM-1 on the surface of endothelial cells facilitates the targeting and the
subsequent extravasation of VLA-4 expressing NPCs to the site of injury [18]. In line with this,
mouse NPCs sorted via FACS for the presence of VLA-4 revealed a more efficient transendo‐
thelial migration in a mouse model of stroke after intracarotid injection [18]. More recently it
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was shown that also the CCR2/CCL2 interaction is substantially involved in the recruitment
of systemically delivered NPCs in a mouse model of stroke [172].
In vitro experiments confirmed that mouse NPCs express many functional receptors on theirs
surfaces, among which the α4 subunit of the integrin VLA-4 [16], the SDF-1α receptor CXCR4
[173] and CD44, a cell-surface glycoprotein that binds to hyaluronic acid (HA) and is expressed
also in activated T cells [174, 175]. Interestingly, NPCs led to the formation of transmigratory
cups, enriched in multiple adhesion molecules such as ICAM-1 and VCAM-1, on the surface
of endothelial cells [175] as previously shown for T lymphocytes diapedesis [176].
Similarly, also immortalized human NPC lines express CD44 [175] and CXCR4 [173]. However,
in a recent study, human NPCs were shown to interact with activated ECs through integrins
α2, α6 and β1 rather than CXCR4 [177]. Further, human NPCs express the receptors CXCR1
and CXCR5, which mediate their in vitro migration across a monolayer of human brain ECs in
response to IL-8/CXCL8 and B lymphocyte chemoattractant (BLC)/CXCL13, chemokines
previously known to favour the trans-endothelial migration of immune cells [178].
All these evidences suggest that systemically injected mouse and human NPCs share the
expression of a variety of functional immune-like receptors, such as functional cell adhesion
molecules (e.g. CD44 and VLA-4) and inflammatory chemokine receptors (e.g. CCR2, CCR5
and CXCR4), giving them a unique leukocyte-like molecular signature. This characteristic,
allowing NPC interaction with activated endothelial and ependymal cells, represents an
essential requirement in the therapeutic paradigm of systemic delivery. Therefore, the
discovery of the specific homing ability of NPCs across the BBB opened new frontiers for the
treatment of CNS diseases, in particular for those diseases characterized by disseminated
damage.
4.3. NPC interaction with the dysfunctional CNS microenvironment: The establishment of
ectopic niches
Consistent data exists reporting the ability of i.v. injected NPCs to cross the BBB and accumu‐
late into the CNS. Here, exogenous NPCs co-exist with different host components, such as ECs,
infiltrating inflammatory cells, activated macrophages/microglia and reactive astrocytes [19].
In this context, the intimate association with ECs, the physical proximity to the vasculature
and the enhanced expression of stem cell regulators and growth factors involved both in
angiogenesis and neurogenesis has been described to play a major role in defining a molecular
architecture reminiscent of prototypical germinal stem cell niches [16]. Within these atypical
ectopic perivascular niches, in addition to hierarchical (mother-to-daughter) communication, a
sophisticated level of cell-to-cell horizontal communication takes place between transplanted
NPCs and resident cells. Recent evidences confirm that NPCs are able to communicate with
host cells via cellular contacts. For instance, functional gap junction formation has been shown
to allow exogenous NPCs to rescue host neurons and their projections in animal models of
Purkinje neurodegeneration. Gap junctions permitted the trans-cellular delivery of homeo‐
stasis-modulating molecules, as well as directly influenced the coordinated activity of the host
network via Ca++ waves. Moreover, hypoxic preconditioning of NPCs before their in vitro
engraftment increased Connexin 43 expression and improved subsequent communication
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with host cells [179]. Possible mechanisms of communication include also secretion of growth
factors, hormones, cytokines, chemokines and small molecular mediators [180], cell-to-cell
interactions via tunnelling nanotubes [181] and secretion of circular membrane vesicles [182],
other than cell-to-cell contacts [183].
Correlative evidence suggest that, depending on local inflammatory milieu, transplanted
NPCs may either remain in the niche while maintaining an undifferentiated state, or move out
from the niche, finally acquiring a terminally differentiated phenotype [16]. When systemically
injected in chronic EAE mice, syngenic NPCs were found almost exclusively in areas of CNS
damage, mainly within the submeningeal space in close proximity to subpial inflammatory
foci (after i.t. stem cell injection), or around post-capillary venules (after i.v. stem cell injection)
[11]. Ten days after transplantation, relatively few cells were found in the CNS parenchyma
and at 30 dpi many of the surviving donor cells were localized deeply within the brain
parenchyma and displayed a marked distribution pattern: most of them were confined within
areas of demyelination and axonal loss, and only very few cells were found within regions
where the myelin architecture was preserved [11]. Similar results were obtained after i.c.v NPC
injection at the peak of EAE in rats: cells entered into the brain or spinal cord parenchyma and
mostly accumulated at sites of inflamed white matter but not into adjacent grey matter regions.
In line with the previous study, after 2 weeks cells had migrated into distant white matter tracts
but, on the contrary, most of them had acquired specific markers of the astroglial and oligo‐
dendroglial lineages [184]. Mouse NPC transplants in rodents affected by EAE are also
associated with significantly reduced glial scar formation [11] and an increased survival and
recruitment of endogenous neural cells participating to the naturally occurring brain repara‐
tive response upon myelin damage [10, 15, 16, 185, 186].
Human NPCs have  shown a  higher  rate  of  cell  integration  after  being  administered  in
different animal models. In particular, the HB1.F3 immortalized cell line, i.v. injected in a
model  of  ischemic  stroke,  were  shown to  enter  the  ischemic  area  and differentiate  into
neurons  and  astrocytes,  similarly  to  what  observed  with  focal  injected  cells  [12,  187].
Transplanted cells  seemed to  adapt  their  fate  accordingly  to  the  region of  engraftment,
showing the appropriate  neuronal  and glial  markers.  NeuN+  and NF+  cells  were identi‐
fied primarily in the CA1 area of the hippocampus and in the dentate gyrus, mixed with
GFAP+ cells. Vimentin, GFAP and NF markers showed a progressive expression during the
first 2-3 weeks after transplantation, suggesting a step-by-step maturation of the cells [187].
The very same line of cells,  injected in a rat  model of ICH [137],  was observed to infil‐
trate the brain, survive and migrate towards the peri-hematomal areas. The cells were found
mainly  differentiating  into  GFAP+  and  NeuN+  cells.  However,  the  rapid  behavioural
recovery observed in ICH rats as soon as 2 weeks after transplantation, suggested that the
NPC therapeutic effect was mainly related to neuroprotection, rather than to integration
into neuronal  circuitry [137,  187],  since the latter  would require longer time to produce
clinical  ameliorations.  A  similar  trend  towards  human  NPC  differentiation  has  been
observed  in  animal  models  of  SCI,  SE  and  HD.  HB1.F3  hNPCs  administered  in  mice
subjected to compression SCI, were observed to differentiate into βIII-tubulin+ neurons at
21  days  after  transplantation  [167].  GABA-immunoreactive  interneurons  were,  instead,
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observed originating from HB1.F3 when systemically administered the day after lithium-
pilocarpine induction of experimental SE in rats [138]. Further, HB1.F3 cells injected 7 days
after  unilateral  quinolinic  acid  (QA)-induced  model  of  HD  in  rats  were  found  to  stay
confined  around  blood  vessels,  mostly  in  the  damaged  hemisphere  and  only  partially
differentiating in GFAP+ and NeuN+ cells at 3 weeks post transplantation [14].
Despite these evidences showing the ability of exogenous NPCs to survive and differentiate
into multiple derivatives according to local cues, the majority of the data provided has
substantially failed to show convincing relevant differentiation and integration of transplanted
NPCs in vivo. It is now quite evident that NPCs (and more generally somatic adult SCs) might
protect the CNS trough mechanisms alternative to direct cell replacement, which imply the
interaction of NPCs with both resident neural and immune cells [7, 188]. Cell replacement is
therefore only one of the multiple ways by which transplanted NPCs can promote tissue repair,
and a much more complex therapeutic scenario should be foreseen. The concept of stem cell
therapeutic plasticity (or functional multipotency) has therefore emerged, describing the different
way(s) NPCs use to interact with tissue-resident vs. infiltrating immune cells, at the level of
the inflammatory tissue context in which they are either transplanted or migrate to after
transplantation. These bystander effects, are mainly represented by neuroprotection, which
might occur both through secretion of soluble factors and cell-to-cell contact interactions and
immunomodulation, intended as the capacity of NPCs to influence the activity of the immune
system in the CNS and/or in the periphery, at the level of secondary lymphoid organs [5, 19].
4.3.1. Tissue trophic effects
NPCs may exert their neuroprotective effect by increasing in situ bioavailability of several
molecules, such as neurotrophins, growth factors and developmental stem cell regulators, thus
promoting the survival and function of endogenous glial and neuronal progenitors that
escaped the primary insults [19].
Mouse NPCs systemically injected in mice affected by middle cerebral artery occlusion
(MCAo) were observed to mostly maintain an undifferentiated phenotype, while accumulat‐
ing at the boundaries of the lesioned area [140, 141]. Tissue survival was associated with a
down regulation of inflammation, glial scar formation and neuronal apoptotic cell death at
both mRNA and protein levels [140]. Increased levels of BDNF, NGF and neurotrophin (NT)-3
were found in the CSF of stroke-affected rats after intra-cisterna magna administration of
NPCs. In addition, immunohistochemical analysis of the injured brain revealed an increase of
MHC class I levels in treated rats [141]. Interestingly, this neuroprotective effect in the ischemic
microenvironment seems to start very soon after the systemic administration of cells. In fact,
data have been provided showing an increase in the gene expression levels of IGF-1, VEGF,
TGF-1β, BDNF and CXCL12/SDF1-α in the NPC-transplanted MCAo brain, as soon as 24 hours
after the acute i.c.v. injection [189]. Further, NPCs have been proved to increase in vivo
vascularisation when administered after stroke, most likely due to their ability to increase the
presence of VEGF, FGF, BDNF and chemoattractant factors (such as SDF-1α), which promote
angiogenesis and mobilization of endogenous endothelial progenitors [18, 190]
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More recently, adult mouse NPCs systemically injected in mice (3 injections few hours after
the injury) suffering from acute contusion SCI, showed an undifferentiated morphology
(similarly to what observed in EAE) at the level of the damaged CNS. Ex vivo RT-PCR analysis
showed NPC-driven up regulation of BDNF, NT-3, NGF, leukemia inhibitory factor (LIF) and
TNF- α only at 48h after treatments, while no differences were observed neither at 24h or 7
days after transplantation [13]. Similarly to what observed by indirect evidence in vivo, real-
time PCR gene expression analysis directly revealed high levels of NGF, BDNF and NT-3 and
glial cell line-derived neurotrophic factor (GDNF) in the transcripts of cultured rat NPCs [141,
191]. In addition, in line with the observed pro-angiogeneic effect in vivo after transplantation
of mouse NPCs in stroke models [18, 190], human NPCs were proved to secrete VEGF in
vitro [192].
All these evidences suggested that the underlying molecular mechanisms by which trans‐
planted  NPCs  instruct  tissue  protection  effects  are  partly  related  to  increased  in  vivo
bioavailability of major neurotrophins [11, 138, 139, 193] able to modulate the host environ‐
ment resulting more permissive to regeneration.  Neurotrophins exert  important  roles  as
mediators in cell cycle regulation, cell survival, and differentiation during development and
adulthood.  The  delivery  of  diffusible  proteins  to  the  CNS  has  been  seen  as  a  possible
therapeutic weapon for neurological diseases. However, because the CNS is likely impene‐
trable for many of these diffusible proteins, NPCs might be envisaged as carrier of neurotro‐
phic factors. To this aim, NPCs have been genetically modified to act as Trojan horses  to
deliver the desired diffusible molecules at the site of injury, thus fostering their innate capacity
to secrete neurotrophic and growth factors  [194].  Among all  the candidate neurotrophic
factors to be delivered, GDNF has shown a potent neuroprotective effect on a variety of
neuronal inflammatory models, such as stroke and PD [195-197]. However, its effects are
generally transient and need consecutive administrations to obtain long-standing results.
NPCs over-expressing GDNF can instead provide durable neuroprotective effects, as shown
with mouse NPCs, transplanted i.c.v in rats 3 days after MCAo [198]. The exogenous cells
resulted in an overall increase of cell survival of endogenous cells after the insult, which in
turn  was  associated  to  a  partial  functional  recovery.  Interestingly,  treated  rats  also  dis‐
played a significant increase of the synaptic proteins synaptophysin and post-synaptic density
protein (PSD)-95, suggesting an enhanced neuronal function and a possible reconstruction
of endogenous neural circuitries after the grafting [198]. Finally, a recent study showed that
the intravenous administration HB1.F3 human NPCs transduced with INF-β and cytosine
deaminase (CD), was able to interfere with toll-like-receptor (TLR)-4 (up-regulated into the
site of injury) suppressing the SCI-induced proliferation of reactive astrocytes and promot‐
ing functional recovery [199]. Other neurotrophic factors, such as BDNF and VEGF, have
been over-expressed in NPCs and mainly tested upon intraparenchymal injection in models
of SCI [200] or ICH [201, 202]. Taken together, these data suggest that the clinical ameliora‐
tion observed in CNS disease animal models are, at least in part, mediated by a multilay‐
ered NPC neurotrophic signature.
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4.3.2. Regulation of the immune system
Considerable evidence of the immune modulatory capacity of NPCs has derived from transplan‐
tation studies through different routes in the EAE model. As mentioned, transplanted NPCs are
consistently found around inflamed blood vessels, in close contact with both endogenous neural
cells (e.g. astrocytes and neurons) and CNS-infiltrating blood-borne CD45+ immune cells [185].
Also, i.c.v. administered NPCs were found to attenuate brain inflammation primarily through
a reduction of perivascular infiltrates and CD3+ T cells with a concomitant increase of CD25+ and
CD25+/CD62L+ regulatory T cells [136]. Interestingly, i.v. injection of NPCs also protects against
chronic neural tissue loss as well as disease-related disability in EAE, via induction of apopto‐
sis of blood-borne CNS-infiltrating encephalitogenic T cells [185]
NPCs have been shown to possess immune modulatory capacity also in models of stroke,
where T cells do not have a major role in the disease pathology. Irrespectively of the route of
administration (systemically vs. intraparechimally), transplanted NPCs migrate towards the
site of infarct in MCAo and ICH models [12, 137, 138, 203-207] and once reached the ischemic
boundary zone (IBZ), grafted NPCs interact with the inflammatory environment. The sub-
acute (delayed) i.v. injection of mouse NPCs after MCAo in mice, significantly down-regulates
multiple RNA species involved in inflammation, including IFN-γ, TNF-α, IL-1β, IL-6 and
leptin receptor [140]. Therefore, NPCs may exert an immune modulatory action, causing a
profound down regulation of inflammatory lymphoid (T cells) and myeloid (macrophages) cells
within inflamed brain areas.
While the inhibition of the T cell responses by NPCs is a quite established concept [208], the
effect of the interaction between transplanted NPCs and microglia/macrophages is still
controversial, mainly because of the non-univocal data regarding the role sustained by
professional phagocytes under CNS inflammatory conditions. In vivo studies have in fact
produced opposite evidences that might underline once more the bimodal action of some
immune regulators [209]. NPC transplantation promote the infiltration of CD11b+ myeloid
cells into the brain of MCAo mice, thus suggesting that myeloid cell activation might be
required for transplanted NPCs to exert part of their neuroprotective action [189]. Indeed,
MCAo mice in which CD11b+ microglia have been selectively ablated showed exacerbation of
the ischemia-dependent brain injury [113]. However, several studies have showed a significant
reduction of microglia/macrophages in the brain of mice, with either ischemic or haemorrhagic
stroke, together with improved neuronal survival and locomotor functions after NPC trans‐
plantation [22, 140]. Also in this case, NPCs have been engineered in order to increase their
immune modulatory capacity. Recently, mouse NPCs were transduced with IL-10, which has
been proved to efficiently suppress EAE symptoms and promote survival of neurons and
oligodendrocytes [210-212]. Mouse NPCs, transduced with a lentiviral vector encoding IL-10,
showed enhanced ability to induce remyelination, neuronal repair and immune suppression
after systemic injection in EAE mice compared to control NPCs [213].
In vitro, NPCs are shown to increase the apoptosis of PLP139-151-specific Th1 pro-inflammatory
(but not Th2 anti-inflammatory) cells through the engagement of death receptors, including
FasL, TNF-related apoptosis-inducing ligand (TRAIL), and APO3L, on the surface of NPCs [16].
Mouse and rat NPCs also inhibit T cell activation and proliferation in response to T cell recep‐
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tor (TCR)-mediated stimuli (e.g., concanavalin A and anti-CD3/anti-CD28) [136, 214]. NPC/T
lymphocyte co-culture experiments suggest that part of the anti-proliferative effect of NPCs
might depend on the inhibition of IL-2 and IL-6 signalling on T lymphocytes [214]. In addi‐
tion, NPCs have shown a selective pro-apoptotic effect on Th17 cells in vitro via a FasL (CD95L)-
dependent mechanism, identifying the axis Fas-Birc3 as an additional survival pathway for
NPCs [215]. Mouse C17.2 NPCs also suppress T-cell proliferation, at least in part, by reactive
production of the soluble mediators nitric oxide (NO) and prostaglandin E2 (PGE2). High levels
of NO and PGE2 are in fact induced in T cells when co-cultured with NPCs. In addition, inducible
NO synthase (iNOS) and microsomal type 1 PGES (mPGES-1) are detected in NPCs in co-
culture with T-cells, suggesting that NO and PGE2 production in NPCs is induced by expo‐
sure to activated T cells [216].
Human NPCs have been proved to suppress the proliferation and alter the cytokine secretion
profiles of activated T cells on both xenogeneic antigen-specific T cells derived from EAE
induced non-human primates (common marmosets), and allogeneic mitogen-activated T cells.
Co-culture of human NPCs with T cells, revealed their immune modulatory capacity through
both direct cell-to-cell contacts as well as via the release of soluble mediators into the culture
medium [15]. Notably, in contrast to the mouse counterpart, human NPCs have a limited
cytotoxicity against T cells in vitro, given that FasL is only barely detectable on their surface.
However, human NPCs exposed to cytokines express high levels of TNF-α, resulting in a
higher cytotoxic potential against monocytes and macrophages [217]. In line with this,
immortalized human NPCs were also proved, trough direct in vitro experiments, to reduce T
cell activation and proliferation. Conditioned media collected from human NSCs (HB1.F3 line)
in vitro, directly suppress the proliferation of activated human T cells through both induction
of apoptosis and cell cycle arrest. Nonetheless, human NPC-released mediators alter the
cytokine production pattern of T lymphocytes, increasing the expression of IL-4, IL-10, TNF-
α, and IFN-γ and decreasing IL-2, thus affecting the overall activation [200].
4.4. NPC interactions with the dysfunctional non-CNS microenvironment
In parallel to the observed immune modulation and neuroprotection into the CNS, other studies
have shown that systemically injected cells may act also outside the injured CNS. Different
studies, in fact, have reported the capacity of NPCs to target and synergize with immune cells
at the level of secondary lymphoid organs (e.g. draining lymph nodes) and the spleen, result‐
ing in the attenuation of the inflammatory response following EAE, stroke and SCI.
It was initially showed in vitro that NPCs strongly inhibited the ability of EAE-derived lympho‐
cytes to produce pro-inflammatory Th1 cytokines in response to MOG35-55  stimulation. In
addition, specifically activated T cells isolated from EAE mice treated with NPCs, were deficient
in their ability to adoptively transfer EAE (to a naïve host), thus suggesting a long-lasting
inhibition of encephalitogenicity of T cells [20]. Further data have been provided about a specific
and almost exclusive targeting of the peripheral immune system in SJL mice with PLP-in‐
duced EAE, in which NPCs had been injected subcutaneously (s.c.) at 3 and 10 dpi [21]. This
alternative administration protocol showed a significant clinical improvement in EAE mice
despite injected cells were never been consistently found into the inflamed CNS. Sub-cutaneous‐
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ly injected, s.c.-injected cells were mainly found accumulating and persisting (up to 2 months)
at the level of the perivascular areas of the draining lymph nodes, where they interacted with
resident cells. Similarly to what observed in the CNS parenchyma, NPCs accumulated as focal
clusters  around blood vessels  of  the  hilum and medullary/paracortical  areas.  Here  they
established close interactions with endothelial cells and cell-to-cell contacts with CD11c+ DCs,
F4/80+ professional phagocytes and MHC class II+ immune cells [21]. Further, ex vivo analyses of
lymph nodes isolated from NPC-treated EAE mice, showed hampered activation and matura‐
tion of myeloid DCs. This was associated, according to both in vivo and in vitro analyses, to the
release of BMP-4 and TNF-α or TLR agonists. The BMP-dependent effect is highly specific for
immune regulatory NPCs and, in turn, leads to the restraint of encephalitogenic T cell expan‐
sion at sites of antigen presentation. In addition to BMP-4, transplanted NPCs modulated the
local increase of major stem cell fate determinants, including BMP-7, the extracellular matrix
protein tenascin C, Shh and Noggin.  The pattern of NPC accumulation,  the secretion of
extracellular matrix proteins and stem cell regulators, and the lack of expression of neural lineage
antigens (e.g. PSA-NCAM, class III β–tubulin, NeuN, NG-2 and GFAP) once more suggest the
establishment of perivascular atypical ectopic niche-like areas in the peripheral lymph nodes,
similarly to what already seen in the CNS [15]. Supported by these experiments, a successive
step forward was undertaken to test NPCs therapeutic capacity in a non-human primate model
of EAE. Systemically injected foetal human NPCs into MOG74-96-immunized common marmo‐
sets delivered at either the clinical onset of the disease or at subclinical occurrence of MRI
detectable brain lesions, were found not only at the level of perivascular inflammatory CNS areas
but also in secondary lymphoid organs. In parallel to these observations, human NPCs inter‐
fere in vitro with a number of key functions, such as the differentiation of myeloid precursor cells
(MPCs) into immature DC (iDC) and the maturation of iDC to functional mature DCs. A
significant impairment of the differentiation of CD14+ MPCs into CD1a+ iDCs has been report‐
ed when MPCs were cultured with granulocyte macrophage colony-stimulating factor (GM-
CSF) and IL-4 in presence of NPCs [15]. In the same study, NPCs influenced the up regulation
of the co-stimulatory molecules CD80, CD86 and MHC-II on LPS-treated DCs, thus impairing
their capacity to induce a proliferative allogeneic response in mixed leukocyte reaction in vitro.
Clinically wise, the i.v. NPC injection resulted more efficacious than the i.t. NPC treatment. This
might be related to either the higher number of surviving cells or to an additional peripheral
effect. Systemic NPCs were, in fact, subjected to selective capturing into cervical lymph nodes
where they persisted up to 3 months while establishing close contacts with blood-borne
inflammatory cells [15].
Similarly to what observed in EAE models, i.v. administered human NPCs, in a rat model of
ICH, revealed a peripheral therapeutic function in attenuating the inflammatory response to
the insult [22]. In line with previous studies, cells were rarely observed into the injured brain
while the majority of NPCs were found distributed within the systemic organs. In particular,
few NPCs were observed in mesenteric lymph nodes while large numbers were detected in
the spleen, especially in the marginal zone area, which is typically enriched in macrophages.
Once again NPCs were found in close contact with immune cells and some of them were
establishing cell-to-cell contact interactions with CD11b+ spleen macrophages. This result was
probably due to the existence of a link between brain and spleen inflammation, called “brain-
spleen inflammatory coupling”. Remarkably, splenectomy prior to ICH has been shown to
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reduce the initial cerebral oedema and inflammatory cell infiltration caused by stroke [22].
NPC accumulation into the spleen, in this case, modulated brain inflammation by reducing
the level of major inflammatory mediators in stroke, such as TNF-α, IL-6 and nuclear factor-
kappa B (NF-κB), and consequently improved neurologic outcome.
It has been recently shown that mouse NPCs (from fully mismatched C57BL/6 mice) co-
transplanted with pancreatic islet under the kidney capsule of Balb/c diabetic mice prevents
acute islet allograft rejection. This effect was related to a significant reduction of CD4+ T cells
and with a concomitant enrichment of CD4+/CD25+/FoxP3+ regulatory T cells in the spleen,
inducing active tolerance. These data suggest that the peripheral immune-modulation exerted
by NPCs could alleviate the immune reaction leading to organ rejection. Unfortunately this
condition appeared strictly associated with the development of NPC-derived tumours mainly
sustained by insulin secretion from the co-transplanted islets [218].
Whether most of the immune regulatory effects of systemically injected NPCs act mainly into
the CNS or in the periphery is still under debate. Peripheral lymphoid organs have been
demonstrated to play an important role in the regulation of the immune responses to myelin
antigens in EAE and a very sophisticated modulation of T-cell self-reactivity is known to take
place [219-221]. A very recent study proposes a molecular mechanism sustaining NPCs
immune modulation capacity in EAE. The preventive (0 dpi) or therapeutic (10 dpi) i.v.
administration of NPCs resulted in their accumulation in lymph nodes and spleen, with rare
cells observed into the CNS and without any evidence of myelin repair. Nevertheless, treated
mice showed partial clinical recovery. Remarkably, the authors achieved the same results even
transplanting NPC conditioned-medium or minimally irradiated NPCs (unable to differenti‐
ate but capable of secreting cytokines and neurotrophins), evidence sustaining a true periph‐
eral function of NPCs. In particular, the observed clinical amelioration seem to be related to
the selective inhibition of encephalitogenic Th17 cell differentiation through secreted factors.
LIF has been identified as the key factor responsible for the observed inhibition of Th17 cell
differentiation and the authors elucidated the signalling pathway behind this novel mecha‐
nism of action, where LIF antagonizes IL-6-induced Th17 cell differentiation through ERK-
dependent inhibition of STAT3 phosphorylation [23]. Further studies will be needed to
establish the absolute relevance of these pre-clinical data in EAE, where peripheral lymphoid
organs play an important role in the regulation of the immune responses to myelin antigens,
and their potential for future applications in MS. All the preclinical data describing NPC
therapeutic effect upon systemic administration are summarized in Table 1.
Disease Model Species Transplant Features ObservedEffect(s)
Proposed
Mechanism(s) Refs
Cell type Cell no./
animal
Route Time
Experimental Autoimmune Encephalomyelitis (EAE)
Acute EAE Rat Rat
neurospheres
1.5-2x104 i.c.v. or
i.t.
Disease
peak
Cell
differentiatio
None [10]
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Disease Model Species Transplant Features ObservedEffect(s)
Proposed
Mechanism(s) Refs
Cell type Cell no./
animal
Route Time
n (neuronal
and glial and
tissue
trophism
Acute EAE Rat Rat
neurospheres
2x104 i.c.v. 0 dpi Immune
regulation
(central)
None [136]
Chronic EAE Mouse Mouse NPCs 1x106 i.v. or i.t. 22 dpi (Low) cell
differentiatio
n and tissue
trophism
Inhibition of
reactive gliosis
[11]
Chronic EAE Mouse Mouse
neurospheres
2.5x103 i.c.v. 6 dpi Immune
regulation
(local)
Reduction of
CNS
inflammatory
infiltrates,
increase of
regulatory T
cells
[139]
Chronic EAE
Passive EAE
Mouse Mouse NPCs 1x106 i.v. 8 dpi Immune
regulation
(peripheral)
Suppression of
encephalitogen
ic T cells
[20]
Chronic EAE Mouse Human ES
cell-derived
NPCs
5x105 i.c.v. 7 dpi Immune
regulation
(local)
Suppression of
encephalitogen
ic T cells
[142]
Chronic EAE Mouse IL-10-
transduced
mouse NPCs
1.5x106 i.v. or
i.c.v.
10, 22 or
30 dpi
Immune
regulation
(local,
peripheral)
and cell
differentiatio
n
Induction of T
cell apoptosis,
promotion of
myelin debris
clearance
[213]
Chronic EAE Mouse Mouse and
human ES
cell-derived
NPCs
2x106 i.v. 0 or 10 dpi Immune
regulation
(peripheral)
LIF-mediated
inhibition of
Th17 cell
differentiation
[23]
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Disease Model Species Transplant Features ObservedEffect(s)
Proposed
Mechanism(s) Refs
Cell type Cell no./
animal
Route Time
Chronic EAE Mouse Mouse MSC-
derived NPCs
3.5x104-6.
1x106
i.t. 21, 28 and
35 dpi
Tissue
trophism
None [258]
Chronic EAE
Passive EAE
Mouse CCR5-
transduced
mouse BM-
derived NPCs
1.5x106 i.v. 22 dpi
(peak)
Immune
regulation
None [259]
Chronic EAE Common
Marmoset
Human NPCs 2-6x106 i.t. or i.v. Disease
onset
Immune
regulation
(central)
Suppression of
encephalitogen
ic T cells,
imparment of
dendritic cell
maturation
[15]
Relapsing EAE Mouse Mouse NPCs 1x106 i.v. Disease
onset or
first
relapse
Immune
regulation
(central)
Induction of T
cell apoptosis
[16]
Relapsing EAE Mouse Mouse NPCs 0.5x106 s.c. 3 and 10
dpi, or 10
dpi only
Immune
regulation
(peripheral)
BMP-4-
dependent
hindrance of
dendritic cell
maturation
[21]
Relapsing EAE Mouse Mouse NPCs
and Olig2-
transduced
NPCs
1.5x105 i.c.v. Disease
onset or
first
relapse
Immune
regulation
(central) and
Tissue
trophism
None [260]
Stroke
MCAo Rat Rat NPCs 1x105 i.t. 2 dpi Cell
differentiatio
n (neuronal)
None [204]
MCAo (10’ or
90’)
Rat Human NPCs 5x106 i.v. 1 dpi Cell
differentiatio
n (neuronal,
glial)
None [12, 187]
MCAo (180’) Rat Rat NPCs 1x105 i.t. 2 dpi Tissue
trophism
Increased
angiogenesis
[190]
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Disease Model Species Transplant Features ObservedEffect(s)
Proposed
Mechanism(s) Refs
Cell type Cell no./
animal
Route Time
MCAo (180’ Rat Human NPCs 1x106 i.v. 2 dpi Tissue
trophism
None [261]
CCAo + global
hypoxia-
ischemia
Mouse Mouse 17.2
NSCs
3x105 i.ca. 2 dpi Tissue
trophism
Increased
angiogenesis
[18]
MCAo (120’) Rat GDNF-
transduced
rat NPCs
5x105 i.c.v. 3 dpi Tissue
trophism,
Cell
differentiatio
n (neuronal)
None [198]
MCAo (45’) Mouse Mouse NPCs 1x106 i.v. 3 dpi Immune
regulation
(local) and
Tissue
trophism
Reduction of
microglial
activation and
neuronal death
[140]
MCAo and
CCAo
Rat Rat NPCs 1.5x105 i.t. 7 dpi Immune
regulation
and tissue
trophism
Neuroprotectio
n mediated by
NGF and
modulation of
class I MHC
expression
[141]
MCAo (90’) Rat HIF-1α-
transduced
rat NPCs
1x106 i.c.v. 1 dpi Tissue
trophism
Promotion of
angiogenesis
[227]
MCAo (45’) Mouse TAT-Hsp70-
transduced
mouse NPCs
1x106 or
5x105
i.v. or
i.p.c.
Acute Tissue
trophism,
reduction of
ROS
formation
and BBB
leakage
Neuroprotectio
n and
enhanced
neurogenesis
[232]
ICH Rat Human NPCs 5x106 i.v. 1 dpi Tissue
trophism,
Cell
differentiatio
Neuroprotectio
n and
integration in
endogenous
[137]
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Disease Model Species Transplant Features ObservedEffect(s)
Proposed
Mechanism(s) Refs
Cell type Cell no./
animal
Route Time
n (glial and
neuronal)
neuronal
circuitries
Spinal Cord Injury (SCI)
Contusion (T8) Mouse Mouse NPCs 1x106
or1x105
i.v. or
i.p.c.
Acute Tissue
trophism
Reduction of
apoptosis and
modulation of
TNF-α
expression
[13]
Compression
(T8)
Mouse Human NPCs 1x107 i.v. 7 dpi Cell
differentiatio
n (neuronal,
glial)
None [167]
Contusion (T12) Mouse Mouse NPCs
and MOG35-55
immunization
5x105 i.c.v. 7 dpi Immune
regulation
(local) and
Tissue
trophism
T-cell mediated
activation of
microglia with
a protective
phenotype
[226]
BBB: blood-brain barrier; BM: bone marrow; BMP-4: bone morphogenetic protein 4; CCAo: common carotid artery
occlusion; CCR5: C-C chemokine receptor type 5; dpi: days post immunization/injury; ES cells: embryonic stem cells; GDNF:
glial-derived neurotrophic factor; HIF-1α: hypoxia-inducible factor 1α; i.ca.: intracarotid; ICH: intracerebral haemorrhage;
i.c.v.: intracerebroventricular; i.p.c.: intraparenchymal (perilesional); i.t.: intrathecal; i.v.: intravenous; LIF: leukemia
inhibitory factor; MCAo: middle cerebral artery occlusion; MSC: mesenchymal stem cells; ROS: reactive oxygen species;
s.c.: subcutaneous; TAT-Hsp70: TAT-heat shock protein.
Table 1. Neuro-immune interaction following systemic neural stem cell transplantation in experimental disease
models.
5. Pros and cons of NPC systemic administration
In parallel to the investigation concerning the principal mechanism(s) sustaining NPC
therapeutic efficacy, other questions, such as (i) the ideal administration route, (ii) the amount
of cells to be transplanted and (iii) the optimal time point for cell delivery need to be answered.
Among the different possible routes of cell administration, intravenous cell delivery represents
one of the most attractive because of its technical simplicity and clinical practicability.
However, i.v. and i.t. administrations result in lower numbers of cells infiltrating the CNS,
compared to local stereotaxic-driven intracerebral injections, a reason why local injections of
cells are commonly preferred in clinical trials (see next section) despite the higher invasiveness
of the procedure. Even though initially investigated for multifocal disorders (e.g. MS), in order
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to deliver exogenous cells to all the disseminated inflammatory foci, all the previous experi‐
mental data suggest that intravenous or intrathecal administration routes could be desirable
even for focal damages, such as those occurring in stroke and spinal cord injury [222]. In
experimental animal studies, i.p.c [223-225], i.v. [137, 185] i.a. [222], i.t. [204, 226] and i.c.v. [142,
227] protocols have been tested so far. However, only few comparative studies have been
conducted, testing pros and cons of the different administration routes. These studies (mainly
in animal models of stroke) evidenced the obvious capacity of intraparenchymal injection to
deliver higher numbers of cells in situ, compared to i.c.v. and i.v. [228]. By contrast, systemic
injections are thought to lead to a wider distribution of cells around the focal lesioned area.
This aspect is extremely important if we consider that human stem cells (and in particular
hNPCs) are still a limited resource [229]. Intravenously injected NPCs are firstly delivered to
peripheral organs, such as lungs, liver, spleen and kidney [16, 230]. This whole-body distri‐
bution of exogenous systemic injected NPCs significantly reduces cell homing to the injured
brain [222]. To avoid this problem, at least partially, intra-arterial administration could be a
valid alternative (possibly coupled with pre-interventional imaging-based planning) to
selectively cover an injured volume supplied by several target vessels. Intracarotid injection
has already been proved to be functional for delivering stem cells in models of stroke, TBI and
SCI, resulting in higher numbers of extravasating cells (20%) compared to i.v. injections [18].
Nevertheless, although the number of cells infiltrating the CNS has been sometimes described
as fundamental, or at least proportional to their therapeutic effect [231], others have shown
that very low numbers of cells [140] can result into similar outcomes (in term of functional
recovery) compared to higher numbers of locally injected cells. This effect may be explained
by the fact that cell replacement is unlikely the only mechanism sustaining stem-cell thera‐
peutic potential. Higher starting numbers of cells, in fact, increase the therapeutic potential of
intracerebral administered cells, but did not affected the efficacy of the i.v. injected cells. This
again suggests that the number of cells is much more important for focal than systemic
injections [232].
Importantly, when evaluating the optimal protocol, we should consider the procedure itself,
so that the risk should not outweigh the benefits of the treatment. From this point of view, i.e.
cell injection might be accompanied by increased mortality during cell delivery, probably due
to further ischemia or thrombosis [233, 234]. By contrast, cell transplantation trough the
vertebral artery, into patients affected by SCI, showed no adverse effects [235].
Another important unsolved issue for experimental stem cell therapies is the ideal time point
of transplantation. As described, the inflammatory activation of the CNS, characterizing MS,
stroke, SCI, epilepsy, AD, PD, HD is necessary for the homing of systemically injected cells.
Because of the rapid and dynamic changes occurring into the CNS during these inflammatory
conditions, the time of transplantation should be evaluated carefully. In fact, cell death,
excitotossicity, reactive oxygen species accumulation, inflammatory cell infiltrations and glial
scar formation, cause a rapid evolution in the damaged tissue, while creating an hostile
microenvironment for the engraftment of exogenous cells. This is important irrespectively to
the route of administration. For example, the acute focal transplantation of cells into the
ischemic brain or the injured spinal cord reduces the therapeutic efficacy of the cells, which
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are subjected to highly inflammatory conditions causing cell death [205, 236]. On the contrary,
the sub acute phase (few days after insult, in rodents) of the injury seems to be characterized
by better conditions for stem cell survival and a permissive microenvironment for tissue repair/
healing [237]. Although higher inflammation generally correlates with higher number of cells
infiltrating the CNS, it has been shown that greater numbers of cells accumulated into the
spinal cord after i.v. injection at 7 dpi compared to 3 and 10 dpi [167]. However, the optimal
time window for cell transplantation is still elusive and depends mainly on the type of
pathology and aim of the treatment. While neuroprotection should be addressed in the early
stage of the inflammatory disease, just after the initial insult, cell replacement and neurore‐
generation should be targeted in a later stage, when the lesion has stabilized. Indeed, admin‐
istration route, number of cells and time window and seem intimately related and it is not so
difficult to envisage a future in which a combination of early i.v. and late i.p.c administration
of different stem cell sources will be enrolled for the treatment of so far incurable CNS
disorders.
6. Clinical trials
In the last two decades the clinical potential of stem cells in the field of regenerative/restorative
medicine has been often matter of debate, mainly because of its inconsistent outcome. As an
example, the first attempt to treat a CNS disorder by means of stem cell transplantation took
place in the ‘80s: autologous adrenal medulla cells were intracerebrally transplanted into the
striatum of PD patients to provide a local source of catecholamine. The study was proved safe
although with minimal beneficial effect. Further, the first intrastriatal grafts of human foetal
ventral mesencephalic (neuronal preparations) tissue have provided proof-of-concept that cell
therapy can work in patients affected by PD [238]. However, subsequent randomized, double-
blind, placebo-controlled trials brought to much more sceptical conclusions because of patients
showing functional decline (post transplantation) due to dyskinesias (graft-induced involun‐
tary movements), originated by excessive graft function [239, 240].
Prospectively, many factors can be contended to (partially) justify these patchy results. First,
it is now clear that different cell types are needed for different diseases. If on one side PD and
amyotrophic lateral sclerosis (ALS) patients will require cells with dopaminergic and motor
neuron properties respectively, on the other side, cell replacement in AD patients is much more
complicated by the necessity to replace a large variety of cell populations lost in different brain
areas. Second, even though initially expected and long-term envisaged, neuronal replacement
and circuitry integration of transplanted NPCs have been poorly proved. Third, it as to be
considered that pre-clinical animal studies only represent models of human conditions, and,
as such, they offer an exceptionally homogeneous platform, where the genetic background,
age, and environment are all alike. Clearly, this is not the case with patients. Further, even if
multiple models have been established to investigate different aspects of a given disease, none
of them can faithfully emulate the human pathology in its complexity [241, 242]. This is
particularly challenging considering the rate of progression and lack of validated surrogate
disease markers typical of many neurodegenerative disorders. While these aspects are most
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likely destined to remain unsolved pitfalls, others (including the amount of cells to be
transplanted, the manipulation protocols used, the time of transplantation, the route of cell
delivery and the statistics adopted to analyse the data) need to be ameliorated through the
establishment of common guidelines. In particular, the International Society for Stem Cell
Research (ISSCR) composed with a group of international experts (scientists, surgeons,
ethicists and patient advocates) “The ISSCR Guidelines for the Clinical Translation of Stem
Cells” [243] to trace a roadmap guiding the application of experimental stem cell therapeutics
in patients. Importantly, when translating into clinical trials, the choice of the “ideal patient”
imposes major scientific and ethical constraints. Indeed, if on one side the treatment of the
most chronic/severe patients who were not able to respond to previous treatment lowers the
blame for a possible ineffectiveness of a therapy, on the other side the scenario offered by such
a compromised tissue may hinder the potential effect of the treatment.
The primary importance of patient’s care dramatically impacts also on the choice of the best
route of cell delivery. Indeed, if one side the intravenous injection allows for a less invasive
procedure, on the other, the number of cells delivered to the site of interest is lower compared
to local injections. Further, the intracerebral transplantation has been widely accepted, by both
clinicians and patients, after years of clinical applications and technical improvements. These,
together with the relatively limited availability of human NPCs explains why most of the
clinical trials started so far have nevertheless favoured the adoption of more invasive proce‐
dures, such as intraparenchymal/intracerebroventricular ones (see Table 2). However, as
discussed, the correlation between the number of cells entering the CNS and their efficacy still
need to be confirmed.
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3 (Foetal,
Brain-
derived,
c-myc
immortal
ized,
Allogene
ic, single
donor)
2-20x106 Single
injection,
Four
Ascendin
g doses,
Intracere
bral
(putame
n)
0.5-5
years
NA AR Keith
Muir,
MD
NCT0115
1124
NA
Neuralst
em, Inc.
at Emory
Universit
y,
Atlanta
(USA)
Amyotro
phic
Lateral
Sclerosis
(ALS)
I 18 > 18 48 NSI-566R
SC
(Foetal,
Spinal
cord-
derived,
Allogene
ic, single
donor)
0.5-1x106 Multiple
injection
s,
Intraspin
al
≥ 1.5
years
Y (≥ 4
months
pt)
AnR Eva
Feldman
, MD,
PhD
NCT0134
8451
[248,
249]
Azienda
Ospedali
era Santa
Maria,
Terni
(Italy)
ALS I 18 20-75 36 Foetal,
Brain-
derived,
Allogene
ic, single
donor
2.5x105/
injection
Multiple
injection
s, Single
dose,
Intraspin
al
> 6
months
NA AR Angelo
Vescovi,
PhD
NCT0164
0067
NA
StemCell
s, Inc. at
Universit
y of
Californi
a, San
Francisco
(USA)
Pelizaeus
Merzbach
er disease
(PMD)
I 4 0.5-5 12 HuCNS-
SC®
3x108 Multiple
injection
s, Single
dose,
Intracere
bral
NA Y (9
months
pt)
AnR Stephen
Huhn,
MD
NCT0100
5004
[250]
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Sponsor
and
place
Disease Trial
phas
e
Patien
ts (no)
Age at
enrolm
ent (y)
Follo
w up
(mont
hs)
Transplant Features Statu
s
Principal
Investig
ator
Trial
Identifier
Outc
ome
and
Note
s
Cell type Cell no./
patient
Route Time
after
disease/
injury
Immune
suppress
ion
StemCell
s, Inc. at
Oregon
Health
and
Science
Universit
y,
Portland
(USA)
Neuronal
Ceroid
Lipofusci
nosis
(NCL)
I 6 1.5-12 13 HuCNS-
SC®
0.5-1x109 Multiple
injection
s, Single
dose,
Intracere
bral
NA Y (12
months
pt)
C Robert
Steiner,
MD
NCT0033
7636
[247]
StemCell
s, Inc.
Retina
Foundati
on of the
Southwe
st, Dallas
(USA)
Age-
related
Macular
Degenera
tion
(AMD)
I/II 16 > 50 12 HuCNS-
SC®
0.2-1x106 Single
injection,
Single
dose,
Subretin
al
NA Y (3
months
pt)
AR David
Birch,
PhD
NCT0163
2527
NA
pt: post-transplant; NA: information not available. AR: Active Recruiting; AnR: Active not Recruiting; C: Completed.
Table 2. Active clinical trials with neural stem/precursor cells.
Other challenging problems that need to be faced when approaching the clinic, are related to
safety, product potency, and manufacturing quality of the cell source. Indeed, principles of
good tissue practice (GTP) and good manufacturing practice (GMP) are mandatory require‐
ments, especially when dealing with cells of human origin [244].
Last, but not least, some major issues related to the long-term safety of the cellular product
need to be solved. It is important to stress how, differently from the classical drug-therapy, a
cell-based treatment cannot be discontinued, since once the cells are within the patient they
cannot be removed. Therefore, long-term pre-clinical data need to be collected before trans‐
lating from the bench to the bed-side to avoid the occurrence of dramatic outcomes, such as
the one involving a young patient suffering of Ataxia Telangiectasia who developed a donor-
derived brain tumour following neural stem cell transplantation [245].
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Nevertheless, translational research did not (and should not) stop. As a matter of fact, the huge
amount of data collected so far led to the development of numerous early stage clinical trials.
There are currently 1750 studies employing the use of stem cells in interventional clinical trials,
among which 280 are testing NPCs. Within the total number of clinical studies, 277 worldwide
open trials involve SCs and patients affected by CNS disorders (Figure 2), such as MS, stroke,
SCI, epilepsy, ALS, PD, AD, HD, neuronal ceroid lipofuscinose (NCL), Pelizaeus–Merzbacher
disease (PMD), age-related macular degeneration (AMD) [246]. Several phase I and II clinical
studies with NPCs (9 in highly debilitating CNS disorders, Table 2) have now been started
with the primary aim to verify the safety (mainly in terms of toxicity) and feasibility - rather
than the efficacy - of the treatment. Further, clinical studies are often accompanied by non-
official secondary end-points usually concerning the potential impact in the clinical outcomes.
These explorative trials have certainly a key role in stem cell medicine development, as both
phase II dose-escalation studies and the inclusion of non-fatal diseases with larger population
bases will definitely be facilitated once human safety will be established.
In May 2006 at Oregon Health and Science University (OHSU, Portland, OR, USA) the first
human study involving the transplantation of allogeneic NPCs was started on a fatal rare
neurometabolic syndrome, such as the NCL Batten’s disease. In this open-label dose-escalating
phase I trial, a total of 6 subjects with infantile and late-infantile NCL were transplanted in a
single-stage procedure. StemCell, Inc. proprietary, single donor allogeneic free-floating
Figure 2. Worldwide open experimental clinical trials involving the use of stem cells for CNS disorders. The map
shows the distribution of open stem cell-based clinical trials enrolling patients affected by CNS pathologies and treat‐
ed with different source of SCs. Figure has been generate by clinicaltrials.gov, using the keywords stem cells AND CNS
diseases; the inclusion criteria were only open studies; while the exclusion criteria where studies with unknown status.
Stem cells in the figure include: neural stem/precursor cells, mesenchymal stem cells from the bone marrow and the
adipose tissue, hematopoietic stem cells, embryonic stem cells.
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cultured, foetal-derived brain human NPCs (HuCNS- SC®) were directly administered to the
cerebral hemispheres and lateral ventricles. Immune suppression was administered for 12
months after transplantation. This study has now been completed with one out of 6 patients
died for disease progression, 11 months after treatment. The cell transplantation and combi‐
nation with prolonged immune suppression were both well tolerated [247].
In September of 2009, NeuralStem, Inc. sponsored a phase I trial in ALS at the Emory University
School of Medicine (Atlanta, GA, USA), using proprietary single donor allogeneic, adherent
cultured, foetal-derived spinal NPCs (NSI-566RSC). NSI-566 cells were surgically implanted
on a total of 12 patients via multiple injections directly into the thoracic spinal cord (either
unilateral or bilateral). The clinical assessments demonstrated no evidence of acceleration of
disease progression with the planned 18 months post-transplantation follow up [248, 249].
StemCell, Inc. is also sponsoring other two phase I trials with HuCNS-SC® in X chromosome
linked connatal leukodistrophy PMD (in which oligodendrocytes cannot myelinate axons) and
AMD. With the PMD trial at the University of California, San Francisco (UCSF, San Francisco,
CA, USA), HuCNS-SC® were directly delivered through multiple injections into the brain of
a total of 4 male patients (clinicaltrials.gov identifier no. NCT01005004). Data regarding this
clinical trial has been recently published [250]. The transplantation procedure, the immuno‐
suppression and the cells were well tolerated by all the 4 patients. No adverse effects related
to the implant were detected. MRI investigation before and after the transplantation of cells,
revealed, after 9 months, a consistent donor cell-derived myelination in situ, in three of the
patients. However, these data are just published and under intense scientific discussion. With
the AMD trial at the Retina Foundation of the Southwest (Dallas, TX, USA), HuCNS-SC® are
being delivered directly into the subretinal space of one eye in a single transplant procedure
in a total 16 patients. The estimated completion date of this study is March 2014 (clinicaltri‐
als.gov identifier no. NCT01632527).
In June 2012, the Glasgow Southern General Hospital (Glasgow, Scotland) enrolled the first
patient (of 12 total) of the dose-escalating Pilot Investigation of Stem Cells in Stroke (PISCES)
phase I trial to be transplanted in a single-stage procedure with direct cerebral (intraparen‐
chymal) delivery of Reneuron, Ltd. proprietary single donor allogeneic adherent cultured, c-
myc immortalized foetal-derived brain human NPCs (CTX0E03) (clinicaltrials.gov identifier
no. NCT01151124).
In March 2011, the University Hospital Balgrist (Zurich, Switzerland) enrolled the first patient
(of 12 total) with chronic thoracic (T2–T11) SCI (3 to 12 months after complete and incomplete
cord injuries) to be transplanted with HuCNS-SC® in a further StemCell, Inc. sponsored phase
I/II clinical trial estimated to be concluded in March 2016. A single dose (20x106 cells) of
HuCNS-SC® has been directly implanted through multiple injections into the thoracic spinal
cord, and immune suppression administered for 9 months after transplantation (clinicaltri‐
als.gov identifier no. NCT01321333). In November 2012 started the consequent long-term
follow up of the 12 patients subjected to HuCNS-SC® transplantation that will last until March
2018 (clinicaltrials.gov identifier no. NCT01725880).
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In June 2012, the Azienda Ospedaliera Santa Maria (Terni, Italy) enrolled the very first of total
18 ALS patients to treat with intraspinally implanted allogeneic free-floating cultured, foetal-
derived brain NPCs. (clinicaltrials.gov identifier no. NCT01640067).
Importantly, there are not yet clinical trials with NPCs in MS. However, a consensus paper has
recently been produced by a group of experts to define the uniform guidelines on the devel‐
opment of haematopoietic and non-haematopoietic stem cell therapies for MS [9]. All the
current clinical trials envolving NPCs for CNS disorders are described in Table 2.
While in this paragraph we offer an overview of the current clinical trials involving solely
human NPCs, it has to be said that, in the light of the neuroprotective/immunomodulatory
(rather than cell replacement) properties attributed to stem cells, the therapeutic plasticity of
cells of non-neural origin are being tested as well. Among these, MSCs are emerging as a good
potential candidate, mainly because of their great accessibility and remarkable proliferation.
Also, growing evidence suggests that other than giving origin to multiple derivatives of the
mesodermal lineage (from which they derive), under particular conditions MSCs seem able to
transdifferentiate into neuro-ectodermal cells in vitro [251-254]. However, this ability to convert
from one lineage to another is still highly questionable and opened to different interpretations.
Several studies have also proved the ability of MSCs to survive, migrate and eventually bring
about functional recovery when transplanted into the CNS of different experimental models
of neurological diseases (for a review see [255]). However, the mechanisms yielding to such
rescue are unlikely ascribable merely to cell replacement.
Since 2006, the advent of induced pluripotent stem cells (iPSCs, [24]) technology has brought
new excitement in medical research and clinical therapy, since these cells provide a valuable
alternative without being constrained by ethical issues and immunological incompatibility
[256]. Although still under debate about their long-term safety, the methods for iPSC genera‐
tion, reprogramming and differentiation efficiency, iPSCs represent a break-trough for both
study of disease mechanisms and investigation of potential new treatments (for a perspective
analysis, see [257]).
The potential impact of this technological platform has been further boosted by the scientific
stream emerged from iPSC technology that is the “direct reprogramming” from one somatic
lineage to another. In fact, the direct conversion of fibroblasts to functional neurons (iN cells)
or iNSCs [25, 26], for example, represents one of the most exciting, ultimate technologies for
future application in CNS pathologies. Thanks to these next generation techniques, it will be
possible to derive virtually unlimited numbers of specific neural/neuronal population
bypassing the pluripotent stage, thus likely eliminating the potential presence of unwanted
undifferentiated cells. However, many issues, such as the purity of the cell preparation, the
use of virus-based technologies and the proper in vivo integration and differentiation still need
to be better addressed. Importantly, the availability of such a high number of cells will release
the intravenous protocol from one of its major limit, thus casting new light on its clinical
potentiality.
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Abbreviations
AD: Alzheimer’s disease
ALS: Amyotrophic lateral sclerosis
APC: Antigen presenting cell
ASCL1: Achaete-scute homolog 1
BBB: Blood brain barrier
BCSFB: Blood-cerebrospinal fluid barrier
BDNF: Brain-derived neurotrophic factor
BLMB: Blood-leptomeningeal barrier
BMP: Bone morphogenetic protein
BMSC: Bone marrow-derived stem cell
CCAo: Common carotid artery occlusion
CCL: Chemokine (C-C motif) ligand
CCR: C-C chemokine receptor
CNS: Central nervous system
CNTF: Ciliary neurotrophic factor
CSF: Cerebrospinal fluid
CXCR: C-X-C chemokine receptor
DCs: dendritic cells
DCX: Doublecortin
DG: Dentate gyrus
DGC: Dentate granule cell
Dlx: Distal-less homeobox
d.p.t.: days post transplantation
EAE: Experimental autoimmune encephalomyelitis
EC: Endothelial cell
ES cells: Embryonic stem cells
FACS: Fluorescence-activated cell sorting
FGF: Fibroblast growth factor
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GABA: Gamma-aminobutyric acid
GCL: Granule cell layer
GDNF: Glial-derived neurotrophic factor
GFAP: Glial-fibrillary acidic protein
GF-CSF: granulocyte macrophage colony stimulating factor
GMP: Good manufacturing practice
GTP: Good tissue practice
HD: Huntington’s disease
hNPC: Human neural stem/precursor cell
Hsp70: Heat shock protein 70
HuCNS-SC: Human CNS stem cell
HVc: hyperstriatum ventrale, pars caudalis
i.a.: Intraartery
i.c.v.: Intracerebroventricular
i.p.c.: Intraparenchyma
i.t.: Intrathecal
i.v.: Intravenous
ICAM: Intercellular adhesion molecule
ICH: Intracerebral hemorrhage
Ig: Immunoglobulin
IGF: Insulin-like growth factor
IL: Interleukin
IML: Inner molecular layer
iN cells: Induced neuronal cells
INF: Interferon
iNOS: inducible nitric oxide synthase
iNSC: Induced neural stem cell
IPC: Intermediate progenitor cell
iPS: Induced pluripotent stem cell
LFA: Leukocyte-function associated antigen
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LIF: Leukemia inhibitory factor
LPS: Lipopolysaccharide
MAdCAM: Mucosal addressin cell adhesion molecule
MCAo: Middle cerebral artery occlusion
MCP: Monocyte chemoattractant protein
MHC: Major histocompatibility complex
MMS: Medial migratory stream
MOG: Myelin oligodendrocyte glycoprotein
MPC: Myeloid precursor cell
MRI: Magnetic resonance imaging
MS: Multiple sclerosis
MSC: Mesenchymal stem cell
NCL: Neuronal ceroid lipofuscinose
NeuN: Neuronal nuclei
NF: Neurofilament
NF-kB: Nuclear factor-kB
NGF: Nerve growth factor
NO: Nitric oxide
NPC: Neural stem/precursor cell
NSC: Neural stem cell
OB: Olfactory bulb
OPC: Oligodendrocyte progenitor cells
PD: Parkinson’s disease
PGE2: prostaglandine 2
PLP: Proteolipid protein
PSA-NCAM: Polysialylated neural cell adhesion molecule
PSGL: P-selectin glycoprotein ligand
pt: Post-transplantation
RA: Radial astrocyte
RMS: Rostral migratory stream
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s.c.: Subcutaneous
SCF: Stem cell factor
SCI: Spinal cord injury
SC: Stem cell
SDF: Stromal cell-derived factor
SE: Status epilepticus
SGZ: Subgranular zone
Shh: Sonic hedgehog
SIDS: Stroke-induced immune depression syndrome
TCR: T cell receptor
TGF: Transforming growth factor
TJ: Tight junction
TLE: Temporal lobe epilepsy
TLR: Toll-like receptor
TNF: Tumor necrosis factor
V-SVZ: Ventricular-subventricular zone
VCAM: Vascular cell adhesion molecule
VEGF: Vascular endothelial growth factor
VLA: Very late antigen
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